◈

Mechanistic Hypotheses

2

Multihit NK-Cell Neoplasia Model

multihit_nk_neoplasia_model EMERGING

Evidence balance 2 support

Recurrent JAK-STAT, RAS-MAPK, DDX3X, TP53/checkpoint, and epigenetic-regulator alterations co-occur and are implicated in malignant NK-cell survival and expansion. No single recurrent pathway is sufficient to explain the fulminant phenotype.

Pathograph links

Malignant NK-Cell Survival and Expansion -> Systemic Blood, Marrow, and Reticuloendothelial Involvement UNKNOWN The malignant NK-cell population involves blood, marrow, liver, and spleen; the clinical evidence does not establish a single direct route of spread.

Malignant NK-Cell Survival and Expansion -> HLH-Like Hyperinflammation UNKNOWN ANKL can accompany a fulminant hemophagocytic inflammatory syndrome, but clinical co-occurrence does not define the complete causal chain.

JAK-STAT Pathway Activation -> Malignant NK-Cell Survival and Expansion UNKNOWN Recurrent JAK-STAT lesions are implicated in ANKL pathogenesis, but the human genomic evidence does not establish a direct edge at this granularity.

RAS-MAPK Pathway Alterations -> Malignant NK-Cell Survival and Expansion UNKNOWN RAS-MAPK alterations are candidate cooperating inputs to malignant NK-cell expansion; a direct causal edge is not established in the cohort.

TP53 Checkpoint and DNA-Repair Impairment -> Malignant NK-Cell Survival and Expansion UNKNOWN TP53/checkpoint impairment is a candidate cooperating input to malignant NK-cell survival, but recurrence evidence alone does not prove directness.

DDX3X Alteration -> Malignant NK-Cell Survival and Expansion UNKNOWN DDX3X alteration is a candidate cooperating input to malignant expansion; direct functional causation is not established by the cohort.

Epigenetic-Regulator Alterations -> Malignant NK-Cell Survival and Expansion UNKNOWN Epigenetic-regulator alterations are candidate cooperating inputs to malignant NK-cell survival; their directness is unresolved.

Systemic Blood, Marrow, and Reticuloendothelial Involvement -> Lymphadenopathy UNKNOWN Lymphadenopathy was reported in the prolonged-prodrome subset; the route from systemic disease to nodal enlargement is not resolved.

Systemic Blood, Marrow, and Reticuloendothelial Involvement -> Hepatosplenomegaly UNKNOWN Systemic ANKL involvement commonly includes concurrent liver and spleen enlargement.

Systemic Blood, Marrow, and Reticuloendothelial Involvement -> Elevated Transaminases UNKNOWN Transaminitis accompanies liver impairment in ANKL; directness from tissue involvement is not established by the cohort.

Systemic Blood, Marrow, and Reticuloendothelial Involvement -> Thrombocytopenia UNKNOWN Severe thrombocytopenia occurs in ANKL, while marrow, inflammatory, and consumptive contributions are not separated by the outcome analysis.

Systemic Blood, Marrow, and Reticuloendothelial Involvement -> Pancytopenia UNKNOWN Cytopenias, including pancytopenia, can accompany the ANKL leukemic and HLH-like inflammatory presentation.

HLH-Like Hyperinflammation -> Fever UNKNOWN Fever accompanies the acute inflammatory presentation; the evidence does not isolate a direct route from this modeled node.

HLH-Like Hyperinflammation -> Increased Ferritin UNKNOWN Hyperferritinemia is a clinical correlate of the HLH-like inflammatory state, with causal directness unresolved.

HLH-Like Hyperinflammation -> Coagulation Dysregulation UNKNOWN HLH-like inflammation and coagulopathy co-occur in ANKL, but the causal intermediates and directness are not resolved.

Coagulation Dysregulation -> Disseminated Intravascular Coagulation UNKNOWN DIC is the overt clinical manifestation of the modeled coagulopathy, but the cited clinical review does not prove a direct edge.

Coagulation Dysregulation -> Hypofibrinogenemia UNKNOWN Low fibrinogen is a reported component of ANKL-associated coagulopathy.

Show evidence (2 references)

DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical

"This suggests that deregulated JAK-STAT signaling alone is unlikely to explain the aggressive course of ANKL"

The genomic study explicitly argues against a single-pathway model and supports a cautious multihit interpretation without proving functional cooperation among the observed alterations.

DOI:10.3390/cancers12102900 SUPPORT Other

"Molecular abnormalities that occur in ANKL can be divided into three major groups: JAK/STAT pathway activation, epigenetic dysregulation, and impairment of TP53 and DNA repair."

The review supports multiple recurrent molecular axes in ANKL.

EBV-Positive Superimposed Branch

ebv_positive_superimposed_branch ALTERNATIVE

Evidence balance 2 support

EBV-positive disease can superimpose an EBV-associated inflammatory context on the multihit neoplastic program. This conditional branch is not an obligatory initiating mechanism because EBV-negative ANKL is recognized.

Pathograph links

EBV-Positive Neoplastic Context -> HLH-Like Hyperinflammation UNKNOWN EBV-positive ANKL can present with an HLH-like inflammatory syndrome; the intervening causal route is not resolved by the clinical evidence.

HLH-Like Hyperinflammation -> Fever UNKNOWN Fever accompanies the acute inflammatory presentation; the evidence does not isolate a direct route from this modeled node.

HLH-Like Hyperinflammation -> Increased Ferritin UNKNOWN Hyperferritinemia is a clinical correlate of the HLH-like inflammatory state, with causal directness unresolved.

HLH-Like Hyperinflammation -> Coagulation Dysregulation UNKNOWN HLH-like inflammation and coagulopathy co-occur in ANKL, but the causal intermediates and directness are not resolved.

Coagulation Dysregulation -> Disseminated Intravascular Coagulation UNKNOWN DIC is the overt clinical manifestation of the modeled coagulopathy, but the cited clinical review does not prove a direct edge.

Coagulation Dysregulation -> Hypofibrinogenemia UNKNOWN Low fibrinogen is a reported component of ANKL-associated coagulopathy.

Show evidence (2 references)

DOI:10.3389/frhem.2024.1413794 SUPPORT Human Clinical

"Here we present a case of ANKL in a patient presenting with EBV-HLH."

The case supports an EBV-positive inflammatory presentation branch without establishing EBV as obligatory transformation evidence.

DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical

"mutations recurrent among our EBV-positive cases, such as STAT3 and DDX3X, have also been reported to occur in EBV- negative cases"

Recurrent molecular lesions in EBV-negative cases show that the neoplastic program is not restricted to EBV-positive ANKL.

?

Discussions and Knowledge Gaps

3

Does the prolonged infectious mononucleosis-like prodrome reported in one retrospective cohort define a reproducible biological subgroup, or a cohort-specific clinical-course pattern within ANKL?

KNOWLEDGE GAP OPEN ankl_proposed_subacute_course_reproducibility

Attached to

progression#Cohort-Proposed Prolonged Prodromal Course in a Subset

Treating the proposed “subacute ANKL” course as an established subtype would overstate evidence from 18 of 113 Han Chinese patients and could obscure differences among later cohorts and classification systems.

Show evidence (1 reference)

PMID:29263371 SUPPORT Human Clinical

"All these data suggested that patients with prolonged prodromal phases, whom we define here as “subacute ANKL”, may represent a clinical subtype of ANKL which differed from the others, whom we define here as “classic ANKL”."

The authors explicitly present the subgroup as a proposed interpretation.

Which mechanisms distinguish EBV-positive and EBV-negative ANKL, and which molecular lesions are shared across both contexts?

KNOWLEDGE GAP OPEN ankl_ebv_positive_negative_mechanistic_relationship

Attached to

pathophysiology#EBV-Positive Neoplastic Context pathophysiology#JAK-STAT Pathway Activation pathophysiology#DDX3X Alteration

EBV is frequent but not obligatory, and recurrent STAT3/DDX3X lesions occur in EBV-negative disease. Resolving shared versus EBV-specific dependencies is necessary before assigning EBV an initiating causal role.

Show evidence (1 reference)

DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical

"mutations recurrent among our EBV-positive cases, such as STAT3 and DDX3X, have also been reported to occur in EBV- negative cases"

Shared recurrent lesions motivate direct comparison of EBV-positive and EBV-negative disease mechanisms.

How should ANKL nomenclature and diagnostic boundaries be reconciled with indolent NK-LGLL/CLPD-NK and extranodal NK/T-cell lymphoma?

INTERPRETATION OPEN ankl_nk_lgll_nktcl_boundary

Attached to

pathophysiology#Malignant NK-Cell Survival and Expansion

A historical MONDO synonym can be read as the distinct indolent NK-LGLL entity, while comparative genomics argues against treating ANKL as merely an advanced extranodal NK/T-cell lymphoma. Integrated classification should preserve these clinical boundaries.

Show evidence (1 reference)

DOI:10.1038/s41467-018-03987-2 SUPPORT Other

"Gain-of-function STAT3 mutations have also been previously described in diseases of varying aggressiveness, such as NKTCL and the relatively indolent T-LGLL and CLPD-NK"

The comparative discussion supports keeping indolent LGL disorders distinct from ANKL despite shared molecular features.

⚙

Pathophysiology

10

EBV-Positive Neoplastic Context

EBER positivity is frequent in ANKL and can accompany an EBV-HLH presentation, but EBV-negative disease is recognized. EBV results therefore define a conditional disease context rather than an obligatory transforming event.

EBV-Positive Superimposed Branch

natural killer cell CL:0000623

cytokine-mediated signaling pathway GO:0019221 ↑ INCREASED

bone marrow UBERON:0002371 blood UBERON:0000178

Downstream

HLH-Like Hyperinflammation EBV-positive ANKL can present with an HLH-like inflammatory syndrome; the intervening causal route is not resolved by the clinical evidence.

Show evidence (2 references)

DOI:10.3389/frhem.2024.1413794 SUPPORT Human Clinical

"Here we present a case of ANKL in a patient presenting with EBV-HLH."

This supports EBV-HLH as a clinically important presentation context for ANKL without proving EBV-mediated transformation.

DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical

"They were also positive for CD2 (10/12), c-MYC (6/8), BCL2 (6/8), CD16 (5/7), EBER (9/12), CD7 (6/11), pSTAT3Tyr705 (3/8), CD8 (2/6), PD-L1 (2/8), CD4 (2/11), CD8 (2/6), and CD158 (1/5)."

EBER was detected in nine of twelve cases, supporting a frequent but non-universal EBV-positive context.

Malignant NK-Cell Survival and Expansion

The neoplastic cells retain NK-lineage markers, particularly CD56 and CD94, while lacking surface T-cell markers such as surface CD3, CD5, and CD57. Their survival and expansion underlie the systemic leukemic population.

Multihit NK-Cell Neoplasia Model

natural killer cell CL:0000623

cell population proliferation GO:0008283 ↑ INCREASED

bone marrow UBERON:0002371 blood UBERON:0000178 liver UBERON:0002107 spleen UBERON:0002106

Downstream

Systemic Blood, Marrow, and Reticuloendothelial Involvement The malignant NK-cell population involves blood, marrow, liver, and spleen; the clinical evidence does not establish a single direct route of spread.

HLH-Like Hyperinflammation ANKL can accompany a fulminant hemophagocytic inflammatory syndrome, but clinical co-occurrence does not define the complete causal chain.

Show evidence (1 reference)

DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical

"The neoplastic cells were positive for CD56 and CD94, and negative for surface CD3, CD5, and CD57 in all cases assessed."

This 12-case clinicopathologic series supports NK-lineage malignant-cell expansion with the characteristic diagnostic immunophenotype.

JAK-STAT Pathway Activation

JAK-STAT pathway activation is a major recurrent molecular abnormality in ANKL. STAT3 mutation and additional JAK-STAT copy-gain or phosphatase lesions provide a growth and survival mechanism and a rationale for pathway-directed drug profiling.

Multihit NK-Cell Neoplasia Model

natural killer cell CL:0000623

STAT3 hgnc:11364

cell surface receptor signaling pathway via JAK-STAT GO:0007259 ↑ INCREASED

Downstream

Malignant NK-Cell Survival and Expansion Recurrent JAK-STAT lesions are implicated in ANKL pathogenesis, but the human genomic evidence does not establish a direct edge at this granularity.

Show evidence (2 references)

DOI:10.3390/cancers12102900 SUPPORT Other

"Molecular abnormalities that occur in ANKL can be divided into three major groups: JAK/STAT pathway activation, epigenetic dysregulation, and impairment of TP53 and DNA repair."

The review identifies JAK/STAT pathway activation as a major molecular abnormality in ANKL.

DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical

"We study 14 ANKL patients using whole-exome sequencing (WES) and identify mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as inDDX3X(29%) and epigenetic modifiers (50%)."

This human tumor genomic study supports recurrent STAT3 mutation in ANKL.

RAS-MAPK Pathway Alterations

Activating RAS-MAPK pathway mutations form another recurrent signaling arm in ANKL and may cooperate with other lesions in the multihit neoplastic model.

Multihit NK-Cell Neoplasia Model

natural killer cell CL:0000623

Downstream

Malignant NK-Cell Survival and Expansion RAS-MAPK alterations are candidate cooperating inputs to malignant NK-cell expansion; a direct causal edge is not established in the cohort.

Show evidence (1 reference)

DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical

"including those leading to the constitutive RAS activation (p.G12D and p.G13D) as well as a BRAF mutation (p.G469A)."

Human tumor sequencing identified activating RAS variants and a BRAF variant in the RAS-MAPK pathway.

TP53 Checkpoint and DNA-Repair Impairment

TP53 mutation, abnormal p53 expression, and broader DNA-repair impairment form a distinct pathophysiologic axis in ANKL. These alterations are most directly linked to loss of cell-cycle checkpoint and apoptosis control.

Multihit NK-Cell Neoplasia Model

natural killer cell CL:0000623

TP53 hgnc:11998

regulation of apoptotic process GO:0042981 ⚠ ABNORMAL

Downstream

Malignant NK-Cell Survival and Expansion TP53/checkpoint impairment is a candidate cooperating input to malignant NK-cell survival, but recurrence evidence alone does not prove directness.

Show evidence (2 references)

DOI:10.3390/cancers12102900 SUPPORT Other

"Molecular abnormalities that occur in ANKL can be divided into three major groups: JAK/STAT pathway activation, epigenetic dysregulation, and impairment of TP53 and DNA repair."

The review separates TP53 and DNA-repair impairment from JAK-STAT and epigenetic mechanisms.

DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical

"TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2 mutations were each detected in 2 of 6 cases."

This clinicopathologic series supports recurrent TP53 mutation in ANKL.

DDX3X Alteration

DDX3X is recurrently altered in ANKL genomic cohorts and was identified as a recurrent gene by two driver-discovery algorithms. Its precise position in the multihit causal hierarchy remains unresolved.

Multihit NK-Cell Neoplasia Model

natural killer cell CL:0000623

DDX3X hgnc:2745

Downstream

Malignant NK-Cell Survival and Expansion DDX3X alteration is a candidate cooperating input to malignant expansion; direct functional causation is not established by the cohort.

Show evidence (1 reference)

DOI:10.1038/s41467-018-03987-2 SUPPORT Computational

"DDX3X, BCOR, and STAT3 were identiﬁed in ANKL as recurrent by both the MutSigCV and Oncodrive-fm algorithms"

Two analytic methods independently identified DDX3X as recurrent in ANKL.

Epigenetic-Regulator Alterations

Epigenetic dysregulation is a distinct recurrent molecular class in ANKL, including mutations in epigenetic regulatory genes such as ASXL1 and TET2 and broader epigenetic-modifier alterations in sequencing cohorts.

Multihit NK-Cell Neoplasia Model

natural killer cell CL:0000623

ASXL1 hgnc:18318 TET2 hgnc:25941

Downstream

Malignant NK-Cell Survival and Expansion Epigenetic-regulator alterations are candidate cooperating inputs to malignant NK-cell survival; their directness is unresolved.

Show evidence (3 references)

DOI:10.3390/cancers12102900 SUPPORT Other

"Molecular abnormalities that occur in ANKL can be divided into three major groups: JAK/STAT pathway activation, epigenetic dysregulation, and impairment of TP53 and DNA repair."

The review identifies epigenetic dysregulation as an independent major molecular abnormality class in ANKL.

DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical

"We study 14 ANKL patients using whole-exome sequencing (WES) and identify mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as inDDX3X(29%) and epigenetic modifiers (50%)."

Whole-exome sequencing supports frequent epigenetic-modifier mutation in ANKL tumors.

DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical

"TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2 mutations were each detected in 2 of 6 cases."

The clinicopathologic sequencing series directly supports recurrent ASXL1 and TET2 mutations in ANKL.

Systemic Blood, Marrow, and Reticuloendothelial Involvement

ANKL is a systemic leukemia with blood and marrow disease and frequent liver, spleen, and nodal involvement. The clinical literature supports this pattern of involvement but does not resolve a single route of tissue dissemination.

Multihit NK-Cell Neoplasia Model

natural killer cell CL:0000623

blood UBERON:0000178 bone marrow UBERON:0002371 liver UBERON:0002107 spleen UBERON:0002106

Downstream

Lymphadenopathy Lymphadenopathy was reported in the prolonged-prodrome subset; the route from systemic disease to nodal enlargement is not resolved.

Hepatosplenomegaly Systemic ANKL involvement commonly includes concurrent liver and spleen enlargement.

Elevated Transaminases Transaminitis accompanies liver impairment in ANKL; directness from tissue involvement is not established by the cohort.

Thrombocytopenia Severe thrombocytopenia occurs in ANKL, while marrow, inflammatory, and consumptive contributions are not separated by the outcome analysis.

Pancytopenia Cytopenias, including pancytopenia, can accompany the ANKL leukemic and HLH-like inflammatory presentation.

Show evidence (2 references)

DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical

"Two distinct patterns of bone marrow involvement were identified: interstitial and sinusoidal."

The clinicopathologic series directly supports marrow involvement.

DOI:10.3390/cancers12102900 SUPPORT Other

"Patients commonly present acutely with fever, constitutional symptoms, hepatosplenomegaly, and often disseminated intravascular coagulation or hemophagocytic syndrome."

The review supports hepatosplenomegaly as part of systemic ANKL.

HLH-Like Hyperinflammation

ANKL can present with a hemophagocytic lymphohistiocytosis-like systemic inflammatory syndrome. This node represents the inflammatory context, not histologic hemophagocytosis and not a claim that every case meets HLH criteria.

EBV-Positive Superimposed Branch Multihit NK-Cell Neoplasia Model

natural killer cell CL:0000623

cytokine-mediated signaling pathway GO:0019221 ↑ INCREASED

blood UBERON:0000178

Downstream

Fever Fever accompanies the acute inflammatory presentation; the evidence does not isolate a direct route from this modeled node.

Increased Ferritin Hyperferritinemia is a clinical correlate of the HLH-like inflammatory state, with causal directness unresolved.

Coagulation Dysregulation HLH-like inflammation and coagulopathy co-occur in ANKL, but the causal intermediates and directness are not resolved.

Show evidence (1 reference)

DOI:10.3389/frhem.2024.1413794 SUPPORT Human Clinical

"Aggressive natural killer cell leukemia (ANKL) is a rare, aggressive hematologic malignancy which often presents as fulminant Epstein-Barr virus (EBV)- driven hemophagocytic lymphohistiocytosis (HLH)."

The report supports an HLH-like inflammatory presentation in EBV-positive ANKL.

Coagulation Dysregulation

ANKL can produce a coagulopathic presentation that includes hypofibrinogenemia and disseminated intravascular coagulation.

EBV-Positive Superimposed Branch Multihit NK-Cell Neoplasia Model

coagulation GO:0050817 ⚠ ABNORMAL

blood UBERON:0000178

Downstream

Disseminated Intravascular Coagulation DIC is the overt clinical manifestation of the modeled coagulopathy, but the cited clinical review does not prove a direct edge.

Hypofibrinogenemia Low fibrinogen is a reported component of ANKL-associated coagulopathy.

Show evidence (1 reference)

DOI:10.3390/cancers12102900 SUPPORT Other

"Patients commonly present acutely with fever, constitutional symptoms, hepatosplenomegaly, and often disseminated intravascular coagulation or hemophagocytic syndrome."

The review supports DIC as part of the acute ANKL presentation.

✶

Histopathology

1

Interstitial and Sinusoidal Bone Marrow Involvement

Bone marrow involvement by ANKL can show interstitial or sinusoidal infiltration patterns, supporting a marrow-based leukemic presentation when interpreted with NK-cell immunophenotyping.

Show evidence (1 reference)

DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical

"Two distinct patterns of bone marrow involvement were identified: interstitial and sinusoidal."

This clinicopathologic series supports the marrow infiltration patterns as a histopathologic feature of ANKL.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

9

Blood 3

Disseminated Intravascular Coagulation HP:0005521

Show evidence (1 reference)

DOI:10.3390/cancers12102900 SUPPORT Other

"Patients commonly present acutely with fever, constitutional symptoms, hepatosplenomegaly, and often disseminated intravascular coagulation or hemophagocytic syndrome."

The abstract directly supports DIC as a feature of the acute ANKL presentation.

Pancytopenia HP:0001876

Show evidence (1 reference)

DOI:10.1155/crh/7796972 SUPPORT Human Clinical

"We present a case of a 71‐year‐old Caucasian male who developed fever, altered mental status, hepatosplenomegaly, pancytopenia, and hemophagocytic lymphohistiocytosis (HLH) and who was ultimately diagnosed with ANKL."

The case report directly supports pancytopenia as part of an ANKL presentation.

Thrombocytopenia HP:0001873

Show evidence (1 reference)

PMID:29263371 SUPPORT Human Clinical

"Univariate analysis revealed the following clinical factors to be significantly associated with shorter survival: thrombocytopenia (<30 × 109/l), elevated serum LDH level (>800 IU/l), hypoalbuminemia (<35 g/l), hyperferritinemia (>1500 IU/l), classic ANKL, treatment without L-asparagine-based..."

The cohort directly identifies severe thrombocytopenia as a prognostic finding.

Cardiovascular 2

Hepatosplenomegaly HP:0001433

Show evidence (1 reference)

DOI:10.3390/cancers12102900 SUPPORT Other

"Patients commonly present acutely with fever, constitutional symptoms, hepatosplenomegaly, and often disseminated intravascular coagulation or hemophagocytic syndrome."

The review abstract directly names hepatosplenomegaly as a common ANKL presentation feature.

Lymphadenopathy HP:0002716

Show evidence (1 reference)

PMID:29263371 SUPPORT Human Clinical

"They manifested infectious mononucleosis (IM)-like symptoms (including fever, lymphocytosis or mononucleosis, lymphadenopathy, and hepatosplenomegaly) for more than 90 days (median: 115 days, range: 90–450 days), prior to the fulminant onset (Table 1)."

The cohort supports lymphadenopathy in the prolonged-prodrome subset.

Metabolism 3

Fever HP:0001945

Show evidence (1 reference)

DOI:10.3390/cancers12102900 SUPPORT Other

"Patients commonly present acutely with fever, constitutional symptoms, hepatosplenomegaly, and often disseminated intravascular coagulation or hemophagocytic syndrome."

The review explicitly includes fever in the common acute presentation.

Increased Ferritin Increased circulating ferritin concentration HP:0003281

Show evidence (2 references)

PMID:29263371 SUPPORT Human Clinical

"Alleviated hyperferritinemia (P < 0.001), transaminitis (ALT, P = 0.009), and hypofibrinogenemia (P = 0.038), suggesting alleviated hemophagocytic lymphohistiocytosis (HLH), liver impairment, and coagulopathy, were also noted at diagnosis in these patients (Table 1 and Supplementary Table S3)."

The subgroup comparison directly documents hyperferritinemia in ANKL.

PMID:29263371 SUPPORT Human Clinical

"Univariate analysis revealed the following clinical factors to be significantly associated with shorter survival: thrombocytopenia (<30 × 109/l), elevated serum LDH level (>800 IU/l), hypoalbuminemia (<35 g/l), hyperferritinemia (>1500 IU/l), classic ANKL, treatment without L-asparagine-based..."

The cohort's univariate analysis directly associates hyperferritinemia above 1500 IU/l with shorter survival.

Elevated Transaminases Elevated circulating hepatic transaminase concentration HP:0002910

Show evidence (1 reference)

PMID:29263371 SUPPORT Human Clinical

"Alleviated hyperferritinemia (P < 0.001), transaminitis (ALT, P = 0.009), and hypofibrinogenemia (P = 0.038), suggesting alleviated hemophagocytic lymphohistiocytosis (HLH), liver impairment, and coagulopathy, were also noted at diagnosis in these patients (Table 1 and Supplementary Table S3)."

The cohort directly documents transaminitis and interprets it as liver impairment.

Other 1

Hypofibrinogenemia HP:0011900

Show evidence (1 reference)

PMID:29263371 SUPPORT Human Clinical

"Alleviated hyperferritinemia (P < 0.001), transaminitis (ALT, P = 0.009), and hypofibrinogenemia (P = 0.038), suggesting alleviated hemophagocytic lymphohistiocytosis (HLH), liver impairment, and coagulopathy, were also noted at diagnosis in these patients (Table 1 and Supplementary Table S3)."

The cohort directly documents hypofibrinogenemia at diagnosis.

🧬

Genetic Associations

5

STAT3 (Recurrent activating somatic mutation and JAK-STAT pathway activation in ANKL)

Gene: STAT3 hgnc:11364 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (3 references)

DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical

"We study 14 ANKL patients using whole-exome sequencing (WES) and identify mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as inDDX3X(29%) and epigenetic modifiers (50%)."

Whole-exome sequencing of human ANKL tumors identified recurrent STAT3 mutations.

DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical

"In total, we identi ﬁed several copy-number alterations (Supplementary Fig. 3) and 419 nonsynonymous somatic muta- tion candidates in tumor-control pairs and 529 in tumor-only samples"

The sequencing workflow explicitly identifies the analyzed alterations as somatic mutation candidates.

DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical

"Markedly, 2/3 discovered STAT3 mutations have previously been reported as activating 12,18, and they localized to exons 20 and 21 encoding the Src homology 2 (SH2) domain mediating the dimerization and activation of STAT3 (Fig. 2a)."

The cohort directly identifies most observed STAT3 variants as previously reported activating mutations in the SH2 domain.

TP53 (Recurrent TP53 alteration and p53 overexpression in ANKL)

Gene: TP53 hgnc:11998 relationship_type: UNKNOWN variant_origin: UNKNOWN

Show evidence (1 reference)

DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical

"TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2 mutations were each detected in 2 of 6 cases."

This clinicopathologic series supports recurrent TP53 mutations in ANKL.

DDX3X (Recurrent somatic mutation in ANKL genomic profiling)

Gene: DDX3X hgnc:2745 relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC

Show evidence (1 reference)

DOI:10.1038/s41467-018-03987-2 SUPPORT Computational

"DDX3X, BCOR, and STAT3 were identiﬁed in ANKL as recurrent by both the MutSigCV and Oncodrive-fm algorithms"

Two driver-discovery algorithms independently identified DDX3X as recurrent in ANKL.

ASXL1 (Epigenetic modifier mutation in ANKL)

Gene: ASXL1 hgnc:18318 relationship_type: UNKNOWN variant_origin: UNKNOWN

Show evidence (1 reference)

DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical

"TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2 mutations were each detected in 2 of 6 cases."

This clinicopathologic series supports ASXL1 mutation as a recurrent epigenetic modifier lesion in ANKL.

TET2 (Epigenetic modifier mutation in ANKL)

Gene: TET2 hgnc:25941 relationship_type: UNKNOWN variant_origin: UNKNOWN

Show evidence (1 reference)

DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical

"TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2 mutations were each detected in 2 of 6 cases."

This clinicopathologic series supports TET2 mutation as a recurrent epigenetic modifier lesion in ANKL.

💊

Medical Actions

3

L-Asparaginase-Containing Chemotherapy (Including SMILE)

Category: Therapeutic Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632

Agent: Asparaginase NCIT:C286

There is no universally standardized initial regimen. Retrospective cohorts support L-asparaginase-containing induction, with a recent cohort reporting higher response and survival with SMILE than with comparator regimens. Selection remains individualized because the evidence is non-randomized and ANKL is rare.

Mechanism Target:

INHIBITS Malignant NK-Cell Survival and Expansion — Cytotoxic L-asparaginase-containing induction is intended to reduce the malignant NK-cell burden.

Show evidence (1 reference)

PMID:41501503 SUPPORT Human Clinical

"The first-line regimens included SMILE (n = 38, 42%), CHOP(-like) (n = 26, 29%), DeVIC (n = 15, 17%), and other L-asparaginase-containing regimens (n = 8, 9%), with the overall response rates of 66%, 31%, 33%, and 50%, respectively."

Clinical response rates support reduction of disease burden by L-asparaginase-containing regimens.

Show evidence (2 references)

PMID:41501503 SUPPORT Human Clinical

"Patients treated with SMILE had significantly better OS than others (2-year OS 30.1% vs. 7.0%; P < 0.001)."

The 2026 retrospective multicenter cohort associates SMILE with improved survival.

PMID:29263371 SUPPORT Human Clinical

"Further subgroup analysis for patients receiving chemotherapy alone revealed significant OS benefit achieved only in patients treated with L-ASPA-based chemotherapy (n = 19, P = 0.008; Supplementary Fig. S4B)."

An earlier retrospective cohort also associated L-asparaginase-based chemotherapy with survival benefit.

Allogeneic Hematopoietic Stem Cell Transplantation

Category: Therapeutic Action: hematopoietic stem cell transplantation Ontology label: Hematopoietic Cell Transplantation NCIT:C15431

Allogeneic hematopoietic stem cell transplantation is considered as consolidation for eligible patients who respond to induction therapy. Retrospective survival associations support this strategy, but do not define a simple direct pathophysiology target.

Show evidence (2 references)

PMID:41501503 SUPPORT Human Clinical

"Prognosis further improved with allogeneic hematopoietic stem cell transplantation (HSCT) (2-year OS 37.2% vs 3.5%; P < 0.001)."

The 2026 retrospective cohort associates allogeneic HSCT with improved two-year survival.

PMID:29263371 SUPPORT Human Clinical

"Patients receiving allo-HSCT exhibited significantly superior survivals when compared to the others without allo-HSCT (P < 0.001)."

The earlier cohort independently supports a survival association with allogeneic transplantation.

Preclinical JAK Inhibition

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: ruxolitinib CHEBI:66919

JAK inhibition is an investigational, preclinical strategy motivated by recurrent JAK-STAT alterations and NK-lineage drug sensitivity. The cited evidence does not establish clinical efficacy in ANKL.

Mechanism Target:

INHIBITS JAK-STAT Pathway Activation — JAK inhibition is intended to suppress recurrent JAK-STAT signaling activity in NK-cell malignancies.

Show evidence (1 reference)

DOI:10.1038/s41467-018-03987-2 SUPPORT In Vitro

"Focusing on targeted agents, we found the JAK inhibitor ruxolitinib and the BCL2 family inhibitor navitoclax to be highly effective across the cell lines (Fig. 3a)."

Drug profiling supports ruxolitinib-mediated JAK inhibition in NK-lineage models, not established ANKL efficacy.

Show evidence (1 reference)

DOI:10.1038/s41467-018-03987-2 SUPPORT In Vitro

"Focusing on targeted agents, we found the JAK inhibitor ruxolitinib and the BCL2 family inhibitor navitoclax to be highly effective across the cell lines (Fig. 3a)."

In vitro drug profiling supports a ruxolitinib treatment rationale, but not an established clinical standard for ANKL.

🔬

Diagnosis

3

Integrated Clinicopathologic Assessment

ANKL diagnosis integrates the systemic clinical course, blood and marrow morphology, and NK-cell immunophenotype while excluding other mature T/NK-cell neoplasms and reactive HLH. EBV studies and molecular findings may provide adjunctive context; no defining molecular lesion is required.

Results: A systemic leukemic NK-cell neoplasm supported by concordant morphology and immunophenotype favors ANKL; EBV positivity refines the disease context but is not required.

Show evidence (2 references)

DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical

"with a surface immunophenotype characteristic of NK cells (CD2+CD3−CD56+), systemic involvement including bone marrow"

The study states the NK-cell immunophenotype and systemic marrow involvement used among the ANKL-specific diagnostic requirements for its human cohort.

PMID:37870698 SUPPORT Other

"WHO-HAEM5 and ICC share basic concepts in classification of T/NK-cell neoplasms, emphasizing integration of clinical presentation, pathology, immunophenotype, and genetics."

The current classification review supports an integrated diagnostic approach for mature T/NK-cell neoplasms.

NK-Cell Flow Cytometry and Immunophenotyping

Diagnosis requires identifying an abnormal NK-cell population and excluding T-cell lineage by immunophenotyping. A typical pattern is CD56/CD94-positive and surface CD3/CD5/CD57-negative.

flow cytometry immunophenotyping NCIT:C113003

Results: An atypical CD3-/CD56+ or CD56+/CD94+ NK-cell population in marrow or blood supports ANKL in the appropriate clinicopathologic context.

Show evidence (2 references)

DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical

"The neoplastic cells were positive for CD56 and CD94, and negative for surface CD3, CD5, and CD57 in all cases assessed."

This case series supports the core diagnostic immunophenotype.

DOI:10.3389/frhem.2024.1413794 SUPPORT Human Clinical

"bone marrow biopsy demonstrated an atypical CD3-/CD56+ natural killer (NK) cell population with diminished CD7 expression consistent with EBV+ ANKL."

The case report demonstrates diagnostic recognition of ANKL by marrow biopsy and NK-cell immunophenotyping.

EBER In Situ Hybridization

EBER testing identifies the frequent but non-universal EBV-positive branch of ANKL.

EBER in situ hybridization NCIT:C138177

Results: EBER positivity supports EBV-positive ANKL; a negative result does not exclude ANKL because not every case in the cited series was EBER-positive.

Show evidence (1 reference)

DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical

"They were also positive for CD2 (10/12), c-MYC (6/8), BCL2 (6/8), CD16 (5/7), EBER (9/12), CD7 (6/11), pSTAT3Tyr705 (3/8), CD8 (2/6), PD-L1 (2/8), CD4 (2/11), CD8 (2/6), and CD158 (1/5)."

The 12-case series reports EBER positivity in nine of twelve cases, demonstrating frequent but non-universal positivity.

📈

Progression

2

Cohort-Proposed Prolonged Prodromal Course in a Subset

Duration: more than 90 days in the reported cohort

A retrospective Han Chinese cohort described an infectious mononucleosis-like prodrome in 18 of 113 patients and proposed, rather than established, a “subacute ANKL” clinical subtype. This entry records a cohort-specific course pattern and is not modeled as a WHO/ICC subtype.

Show evidence (2 references)

PMID:29263371 SUPPORT Human Clinical

"Intriguingly, a subacute clinical course was demonstrated in 18 ANKL patients (15.93%, 18/113)."

The cohort quantifies the proposed prolonged-prodrome subset.

PMID:29263371 SUPPORT Human Clinical

"All these data suggested that patients with prolonged prodromal phases, whom we define here as “subacute ANKL”, may represent a clinical subtype of ANKL which differed from the others, whom we define here as “classic ANKL”."

The authors explicitly frame the classification as a proposal.

Fulminant Presentation and Early Mortality

Duration: often weeks to months

ANKL remains highly lethal. Median survival of two months and 55 days came from a 12-case clinicopathologic series and a 2003–2016 Han Chinese cohort, respectively, and should not be treated as timeless universal estimates. The ANKL22 study, published in 2026, analyzed 108 evaluable patients diagnosed during 2000–2021 and reported median overall survival of 5.5 months and two-year survival of 18.7%, with better outcomes associated with SMILE and allogeneic HSCT.

Show evidence (5 references)

DOI:10.1097/pas.0000000000001518 SUPPORT Human Clinical

"Patients had very poor outcomes despite intensive chemotherapy, with a median survival of 2 months."

The 12-case series directly supports very poor prognosis and short median survival.

PMID:29263371 SUPPORT Human Clinical

"The median OS was only 55 days (Supplementary Tables S2) and 1-year survival rate was only 4.42% (5/113; Supplementary Fig. S1B), which indicated a dismal outcome of ANKL."

The historical 113-patient cohort supports very poor survival in its specific population and treatment era.

PMID:41501503 SUPPORT Human Clinical

"We retrospectively collected 126 ANKL patients diagnosed between 2000 and 2021 from 71 institutes; 108 were evaluable for analysis to characterize the recent advances."

The study dates the diagnosis interval and identifies the 108-patient evaluable cohort.

+ 2 more references

🦠

Infectious Agent

1

Epstein-Barr Virus

EBV is frequently associated with ANKL but is not obligatory. EBER positivity within an aberrant NK-cell population supports an EBV-positive disease branch; EBV-HLH without demonstrable neoplasia remains an overlapping presentation and differential context.

Epstein-Barr virus NCBITaxon:10376

Show evidence (1 reference)

DOI:10.3389/frhem.2024.1413794 SUPPORT Human Clinical

"Aggressive natural killer cell leukemia (ANKL) is a rare, aggressive hematologic malignancy which often presents as fulminant Epstein-Barr virus (EBV)- driven hemophagocytic lymphohistiocytosis (HLH)."

This human case report supports EBV-HLH as an important ANKL presentation context while not implying that every ANKL case is EBV-driven.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Aggressive NK-cell Leukemia:

EBV-Driven Hemophagocytic Lymphohistiocytosis Without Neoplasia

Overlapping Features EBV-HLH can be the initial presentation of ANKL, but EBV-HLH without a malignant NK/T-cell population is a key differential diagnosis during early evaluation.

Distinguishing Features

Detection of an atypical CD3-negative, CD56-positive NK-cell population in marrow supports ANKL rather than isolated EBV-HLH.

Show evidence (2 references)

DOI:10.3389/frhem.2024.1413794 SUPPORT Human Clinical

"This case highlights the diagnostic challenges of ANKL given the lack of standardized diagnostic criteria, the importance of considering T/NK cell malignancies in the differential diagnosis of EBV-HLH, and adds to the literature on this rare disease."

This case report explicitly states that T/NK malignancies must be considered in the differential diagnosis of EBV-HLH.

DOI:10.3389/frhem.2024.1413794 SUPPORT Human Clinical

"bone marrow biopsy demonstrated an atypical CD3-/CD56+ natural killer (NK) cell population with diminished CD7 expression consistent with EBV+ ANKL."

The case directly supports identifying an aberrant NK-cell population in marrow when ANKL presents as EBV-HLH.

Extranodal NK/T-Cell Lymphoma

Overlapping Features Extranodal NK/T-cell lymphoma is another EBV-associated NK/T malignancy with overlapping immunophenotypic, molecular, and clinical features. ANKL should not be modeled simply as a more advanced leukemic form of extranodal NK/T-cell lymphoma; integrated anatomic and clinicopathologic assessment is required.

Distinguishing Features

A systemic leukemic blood-and-marrow presentation supports ANKL, but no single recurrent mutation reliably resolves the boundary.

Show evidence (3 references)

DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical

"arguing against the hypothesis that ANKL would represent a more advanced form of NKTCL."

Comparative genomic analysis argues against treating ANKL as merely an advanced form of extranodal NK/T-cell lymphoma.

DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical

"ANKL diagnosis was made according to the WHO classi ﬁcation, with a surface immunophenotype characteristic of NK cells (CD2+CD3−CD56+), systemic involvement including bone marrow and/or per- ipheral blood and an aggressive clinical course as minimum requirements for diagnosis."

The study's WHO-based inclusion criteria support the systemic blood or marrow presentation used to distinguish ANKL.

DOI:10.1038/s41467-018-03987-2 SUPPORT Human Clinical

"closely related extranodal NK/T-cell lymphoma, nasal type (NKTCL), an extranodal lymphoma commonly presenting in the nasal cavity"

The comparative discussion supports the characteristic extranodal nasal presentation of NKTCL.

Chronic NK-Cell Lymphoproliferative Disorder (NK-LGLL/CLPD-NK)

Overlapping Features Chronic NK-cell lymphoproliferative disorder is a distinct, relatively indolent NK-cell proliferation that should not be conflated with fulminant ANKL.

Distinguishing Features

A chronic indolent NK-cell lymphocytosis favors NK-LGLL/CLPD-NK; fulminant systemic leukemia with organ involvement and HLH-like inflammation favors ANKL.

Show evidence (1 reference)

DOI:10.1038/s41467-018-03987-2 SUPPORT Other

"Gain-of-function STAT3 mutations have also been previously described in diseases of varying aggressiveness, such as NKTCL and the relatively indolent T-LGLL and CLPD-NK"

The study explicitly treats T-LGLL/CLPD-NK as relatively indolent comparators rather than synonyms for fulminant ANKL.

Chronic Active EBV Disease and Other EBV-Positive T/NK Lymphoproliferative Disorders

Overlapping Features Chronic active EBV disease and related EBV-positive T/NK lymphoproliferative disorders can precede or mimic ANKL, particularly during prolonged systemic symptoms. Age, tempo, morphology, immunophenotype, and demonstration of a malignant NK-cell population must be integrated.

Distinguishing Features

A chronic EBV-associated course without a demonstrable aggressive leukemic NK-cell neoplasm favors chronic active EBV disease; abrupt fulminant systemic leukemia favors ANKL.

Show evidence (1 reference)

PMID:29263371 SUPPORT Human Clinical

"CAEBV is an indolent disease primarily affecting children and young adults4. While ANKL usually presents a relatively acute disease mainly occurs in the middle-aged population, even though a subacute clinical course may manifest in a subset of patients."

The cohort discussion contrasts the usual age and tempo of CAEBV and ANKL while acknowledging a prolonged-course ANKL subset.

🔬

Clinical Trials

3

NCT03719105 RECRUITING

Recruiting early-phase I pilot chemoimmunotherapy study using modified SMILE-style induction for advanced NK lymphoma/leukemia followed by allogeneic stem cell transplant for responders.

Show evidence (1 reference)

clinicaltrials:NCT03719105 SUPPORT Human Clinical

"Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia"

The trial summary directly describes the ANKL-relevant induction regimen for advanced NK lymphoma/leukemia.

NCT03623087 PHASE_III UNKNOWN

Phase III SIMPLE chemotherapy study for NK/T-cell malignancies, derived from a PIGLETS protocol used in extranodal NK/T-cell lymphoma and aggressive NK leukemia. The registry currently reports unknown status.

Show evidence (1 reference)

clinicaltrials:NCT03623087 SUPPORT Human Clinical

"NK malignancies consist of two different clinical entities, extranodal NK/T cell lymphoma and aggressive NK leukaemia."

The trial summary explicitly includes aggressive NK leukemia in the NK malignancy population targeted by the chemotherapy study.

NCT05863234 RECRUITING

Recruiting phase I/II dose-escalation clinical trial evaluating repeated continuous intravenous PPMX-T003 in aggressive NK-cell leukemia.

Show evidence (1 reference)

clinicaltrials:NCT05863234 SUPPORT Human Clinical

"This is Phase I/II Dose-Escalation Study to evaluate the tolerability, safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia."

The trial summary directly supports an ANKL-specific PPMX-T003 clinical trial.

{ }

Source YAML

click to show

name: Aggressive NK-cell Leukemia
creation_date: "2026-05-11T17:49:12Z"
description: >-
  Aggressive NK-cell leukemia is a rare, fulminant mature NK-cell hematologic
  malignancy. It commonly presents as an acute systemic inflammatory and
  leukemic illness with fever, hepatosplenomegaly, cytopenias, coagulopathy,
  hemophagocytic lymphohistiocytosis-like inflammation, and rapid multiorgan
  complications. EBV association is frequent but not obligatory. Molecular
  evidence supports a multihit model involving JAK-STAT and RAS-MAPK signaling,
  DDX3X, TP53/checkpoint impairment, and epigenetic-regulator alterations;
  JAK-STAT activation alone does not explain the aggressive course. There is no
  universally standardized initial regimen, but retrospective cohorts support
  L-asparaginase-containing chemotherapy, particularly SMILE, followed by
  allogeneic hematopoietic stem cell transplantation in responding eligible
  patients. Outcomes remain poor, although recent cohorts report longer survival
  than historical series.
categories:
- Hematologic Malignancy
- Mature NK-Cell Neoplasm
- Rare Cancer
synonyms:
- ANKL
- aggressive NK-cell leukemia/lymphoma
- aggressive natural killer cell leukemia
disease_term:
  preferred_term: aggressive NK-cell leukemia
  term:
    id: MONDO:0019470
    label: aggressive NK-cell leukemia
mechanistic_hypotheses:
- hypothesis_group_id: multihit_nk_neoplasia_model
  hypothesis_label: Multihit NK-Cell Neoplasia Model
  status: EMERGING
  description: >-
    Recurrent JAK-STAT, RAS-MAPK, DDX3X, TP53/checkpoint, and epigenetic-regulator
    alterations co-occur and are implicated in malignant NK-cell survival and
    expansion. No single recurrent pathway is sufficient to explain the fulminant
    phenotype.
  evidence:
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This suggests that deregulated JAK-STAT signaling alone is unlikely to
      explain the aggressive course of ANKL
    explanation: >-
      The genomic study explicitly argues against a single-pathway model and
      supports a cautious multihit interpretation without proving functional
      cooperation among the observed alterations.
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Molecular abnormalities that occur in ANKL can be divided into three
      major groups: JAK/STAT pathway activation, epigenetic dysregulation, and
      impairment of TP53 and DNA repair.
    explanation: >-
      The review supports multiple recurrent molecular axes in ANKL.
- hypothesis_group_id: ebv_positive_superimposed_branch
  hypothesis_label: EBV-Positive Superimposed Branch
  status: ALTERNATIVE
  description: >-
    EBV-positive disease can superimpose an EBV-associated inflammatory context
    on the multihit neoplastic program. This conditional branch is not an
    obligatory initiating mechanism because EBV-negative ANKL is recognized.
  evidence:
  - reference: DOI:10.3389/frhem.2024.1413794
    reference_title: "Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we present a case of ANKL in a patient presenting with EBV-HLH.
    explanation: >-
      The case supports an EBV-positive inflammatory presentation branch without
      establishing EBV as obligatory transformation evidence.
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      mutations recurrent among our EBV-positive cases, such as STAT3 and DDX3X,
      have also been reported to occur in EBV- negative cases
    explanation: >-
      Recurrent molecular lesions in EBV-negative cases show that the neoplastic
      program is not restricted to EBV-positive ANKL.
infectious_agent:
- name: Epstein-Barr Virus
  infectious_agent_term:
    preferred_term: Epstein-Barr virus
    term:
      id: NCBITaxon:10376
      label: human gammaherpesvirus 4
  description: >-
    EBV is frequently associated with ANKL but is not obligatory. EBER positivity
    within an aberrant NK-cell population supports an EBV-positive disease branch;
    EBV-HLH without demonstrable neoplasia remains an overlapping presentation
    and differential context.
  evidence:
  - reference: DOI:10.3389/frhem.2024.1413794
    reference_title: "Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Aggressive natural killer cell leukemia (ANKL) is a rare, aggressive
      hematologic malignancy which often presents as fulminant Epstein-Barr
      virus (EBV)- driven hemophagocytic lymphohistiocytosis (HLH).
    explanation: >-
      This human case report supports EBV-HLH as an important ANKL presentation
      context while not implying that every ANKL case is EBV-driven.
pathophysiology:
- name: EBV-Positive Neoplastic Context
  description: >-
    EBER positivity is frequent in ANKL and can accompany an EBV-HLH presentation,
    but EBV-negative disease is recognized. EBV results therefore define a
    conditional disease context rather than an obligatory transforming event.
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  - preferred_term: blood
    term:
      id: UBERON:0000178
      label: blood
  biological_processes:
  - preferred_term: cytokine-mediated signaling pathway
    modifier: INCREASED
    term:
      id: GO:0019221
      label: cytokine-mediated signaling pathway
  evidence:
  - reference: DOI:10.3389/frhem.2024.1413794
    reference_title: "Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we present a case of ANKL in a patient presenting with EBV-HLH.
    explanation: >-
      This supports EBV-HLH as a clinically important presentation context for
      ANKL without proving EBV-mediated transformation.
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They were also positive for CD2 (10/12), c-MYC (6/8), BCL2 (6/8), CD16
      (5/7), EBER (9/12), CD7 (6/11), pSTAT3Tyr705 (3/8), CD8 (2/6), PD-L1
      (2/8), CD4 (2/11), CD8 (2/6), and CD158 (1/5).
    explanation: >-
      EBER was detected in nine of twelve cases, supporting a frequent but
      non-universal EBV-positive context.
  downstream:
  - target: HLH-Like Hyperinflammation
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - ebv_positive_superimposed_branch
    description: >-
      EBV-positive ANKL can present with an HLH-like inflammatory syndrome; the
      intervening causal route is not resolved by the clinical evidence.
    evidence:
    - reference: DOI:10.3389/frhem.2024.1413794
      reference_title: "Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Here we present a case of ANKL in a patient presenting with EBV-HLH.
      explanation: >-
        The case establishes co-presentation of EBV-positive ANKL and HLH, while
        edge directness remains unknown.
- name: Malignant NK-Cell Survival and Expansion
  description: >-
    The neoplastic cells retain NK-lineage markers, particularly CD56 and CD94,
    while lacking surface T-cell markers such as surface CD3, CD5, and CD57.
    Their survival and expansion underlie the systemic leukemic population.
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  locations:
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  - preferred_term: blood
    term:
      id: UBERON:0000178
      label: blood
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  - preferred_term: spleen
    term:
      id: UBERON:0002106
      label: spleen
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The neoplastic cells were positive for CD56 and CD94, and negative for
      surface CD3, CD5, and CD57 in all cases assessed.
    explanation: >-
      This 12-case clinicopathologic series supports NK-lineage malignant-cell
      expansion with the characteristic diagnostic immunophenotype.
  downstream:
  - target: Systemic Blood, Marrow, and Reticuloendothelial Involvement
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    description: >-
      The malignant NK-cell population involves blood, marrow, liver, and spleen;
      the clinical evidence does not establish a single direct route of spread.
    evidence:
    - reference: DOI:10.1097/pas.0000000000001518
      reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Two distinct patterns of bone marrow involvement were identified:
        interstitial and sinusoidal.
      explanation: >-
        The series directly documents marrow involvement by the neoplastic
        disease while edge directness remains unresolved.
  - target: HLH-Like Hyperinflammation
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    description: >-
      ANKL can accompany a fulminant hemophagocytic inflammatory syndrome, but
      clinical co-occurrence does not define the complete causal chain.
    evidence:
    - reference: DOI:10.3390/cancers12102900
      reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Patients commonly present acutely with fever, constitutional symptoms,
        hepatosplenomegaly, and often disseminated intravascular coagulation or
        hemophagocytic syndrome.
      explanation: >-
        The review supports the association between systemic ANKL and an
        HLH-like presentation; the edge is conservatively typed unknown.
- name: JAK-STAT Pathway Activation
  conforms_to: "jak_stat_pathway_activation#Constitutive STAT Activation and Nuclear Translocation"
  description: >-
    JAK-STAT pathway activation is a major recurrent molecular abnormality in
    ANKL. STAT3 mutation and additional JAK-STAT copy-gain or phosphatase
    lesions provide a growth and survival mechanism and a rationale for
    pathway-directed drug profiling.
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  genes:
  - preferred_term: STAT3
    term:
      id: hgnc:11364
      label: STAT3
  biological_processes:
  - preferred_term: cell surface receptor signaling pathway via JAK-STAT
    modifier: INCREASED
    term:
      id: GO:0007259
      label: cell surface receptor signaling pathway via JAK-STAT
  evidence:
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Molecular abnormalities that occur in ANKL can be divided into three
      major groups: JAK/STAT pathway activation, epigenetic dysregulation, and
      impairment of TP53 and DNA repair.
    explanation: >-
      The review identifies JAK/STAT pathway activation as a major molecular
      abnormality in ANKL.
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We study 14 ANKL patients using whole-exome sequencing (WES) and identify
      mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as
      inDDX3X(29%) and epigenetic modifiers (50%).
    explanation: >-
      This human tumor genomic study supports recurrent STAT3 mutation in ANKL.
  downstream:
  - target: Malignant NK-Cell Survival and Expansion
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    description: >-
      Recurrent JAK-STAT lesions are implicated in ANKL pathogenesis, but the
      human genomic evidence does not establish a direct edge at this granularity.
    evidence:
    - reference: DOI:10.1038/s41467-018-03987-2
      reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We study 14 ANKL patients using whole-exome sequencing (WES) and identify
        mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as
        inDDX3X(29%) and epigenetic modifiers (50%).
      explanation: >-
        The tumor cohort supports recurrent JAK-STAT lesions; causal directness
        is intentionally left unknown.
- name: RAS-MAPK Pathway Alterations
  description: >-
    Activating RAS-MAPK pathway mutations form another recurrent signaling arm
    in ANKL and may cooperate with other lesions in the multihit neoplastic model.
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  evidence:
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      including those leading to the constitutive RAS activation (p.G12D and
      p.G13D) as well as a BRAF mutation (p.G469A).
    explanation: >-
      Human tumor sequencing identified activating RAS variants and a BRAF
      variant in the RAS-MAPK pathway.
  downstream:
  - target: Malignant NK-Cell Survival and Expansion
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    description: >-
      RAS-MAPK alterations are candidate cooperating inputs to malignant NK-cell
      expansion; a direct causal edge is not established in the cohort.
    evidence:
    - reference: DOI:10.1038/s41467-018-03987-2
      reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We study 14 ANKL patients using whole-exome sequencing (WES) and identify
        mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as
        inDDX3X(29%) and epigenetic modifiers (50%).
      explanation: >-
        The cohort supports recurrent RAS-MAPK lesions while not resolving edge
        directness.
- name: TP53 Checkpoint and DNA-Repair Impairment
  description: >-
    TP53 mutation, abnormal p53 expression, and broader DNA-repair impairment
    form a distinct pathophysiologic axis in ANKL. These alterations are most
    directly linked to loss of cell-cycle checkpoint and apoptosis control.
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  genes:
  - preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  biological_processes:
  - preferred_term: regulation of apoptotic process
    modifier: ABNORMAL
    term:
      id: GO:0042981
      label: regulation of apoptotic process
  evidence:
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Molecular abnormalities that occur in ANKL can be divided into three
      major groups: JAK/STAT pathway activation, epigenetic dysregulation, and
      impairment of TP53 and DNA repair.
    explanation: >-
      The review separates TP53 and DNA-repair impairment from JAK-STAT and
      epigenetic mechanisms.
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2
      mutations were each detected in 2 of 6 cases.
    explanation: >-
      This clinicopathologic series supports recurrent TP53 mutation in ANKL.
  downstream:
  - target: Malignant NK-Cell Survival and Expansion
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    description: >-
      TP53/checkpoint impairment is a candidate cooperating input to malignant
      NK-cell survival, but recurrence evidence alone does not prove directness.
    evidence:
    - reference: DOI:10.3390/cancers12102900
      reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Molecular abnormalities that occur in ANKL can be divided into three
        major groups: JAK/STAT pathway activation, epigenetic dysregulation, and
        impairment of TP53 and DNA repair.
      explanation: >-
        The review supports this molecular axis while the edge remains
        conservatively typed unknown.
- name: DDX3X Alteration
  description: >-
    DDX3X is recurrently altered in ANKL genomic cohorts and was identified as a
    recurrent gene by two driver-discovery algorithms. Its precise position in
    the multihit causal hierarchy remains unresolved.
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  genes:
  - preferred_term: DDX3X
    term:
      id: hgnc:2745
      label: DDX3X
  evidence:
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      DDX3X, BCOR, and STAT3 were identiﬁed in ANKL as recurrent by both the
      MutSigCV and Oncodrive-fm algorithms
    explanation: >-
      Two analytic methods independently identified DDX3X as recurrent in ANKL.
  downstream:
  - target: Malignant NK-Cell Survival and Expansion
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    description: >-
      DDX3X alteration is a candidate cooperating input to malignant expansion;
      direct functional causation is not established by the cohort.
    evidence:
    - reference: DOI:10.1038/s41467-018-03987-2
      reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Among the most recurrently mutated genes in ANKL were DDX3X (29%, 4/14
        patients) and STAT3 (21%, 3/14 patients) (Fig. 1d).
      explanation: >-
        The cohort supports recurrence but not a direct causal edge.
- name: Epigenetic-Regulator Alterations
  description: >-
    Epigenetic dysregulation is a distinct recurrent molecular class in ANKL,
    including mutations in epigenetic regulatory genes such as ASXL1 and TET2
    and broader epigenetic-modifier alterations in sequencing cohorts.
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  genes:
  - preferred_term: ASXL1
    term:
      id: hgnc:18318
      label: ASXL1
  - preferred_term: TET2
    term:
      id: hgnc:25941
      label: TET2
  evidence:
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Molecular abnormalities that occur in ANKL can be divided into three
      major groups: JAK/STAT pathway activation, epigenetic dysregulation, and
      impairment of TP53 and DNA repair.
    explanation: >-
      The review identifies epigenetic dysregulation as an independent major
      molecular abnormality class in ANKL.
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We study 14 ANKL patients using whole-exome sequencing (WES) and identify
      mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as
      inDDX3X(29%) and epigenetic modifiers (50%).
    explanation: >-
      Whole-exome sequencing supports frequent epigenetic-modifier mutation in
      ANKL tumors.
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2
      mutations were each detected in 2 of 6 cases.
    explanation: >-
      The clinicopathologic sequencing series directly supports recurrent ASXL1
      and TET2 mutations in ANKL.
  downstream:
  - target: Malignant NK-Cell Survival and Expansion
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    description: >-
      Epigenetic-regulator alterations are candidate cooperating inputs to
      malignant NK-cell survival; their directness is unresolved.
    evidence:
    - reference: DOI:10.1038/s41467-018-03987-2
      reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We also detected mutations in epigenetic regulators and histone-modifying
        enzymes in 7/14 patients
      explanation: >-
        The cohort supports recurrent epigenetic-regulator lesions while not
        establishing direct causation.
- name: Systemic Blood, Marrow, and Reticuloendothelial Involvement
  description: >-
    ANKL is a systemic leukemia with blood and marrow disease and frequent liver,
    spleen, and nodal involvement. The clinical literature supports this pattern
    of involvement but does not resolve a single route of tissue dissemination.
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  locations:
  - preferred_term: blood
    term:
      id: UBERON:0000178
      label: blood
  - preferred_term: bone marrow
    term:
      id: UBERON:0002371
      label: bone marrow
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  - preferred_term: spleen
    term:
      id: UBERON:0002106
      label: spleen
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two distinct patterns of bone marrow involvement were identified:
      interstitial and sinusoidal.
    explanation: >-
      The clinicopathologic series directly supports marrow involvement.
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Patients commonly present acutely with fever, constitutional symptoms,
      hepatosplenomegaly, and often disseminated intravascular coagulation or
      hemophagocytic syndrome.
    explanation: >-
      The review supports hepatosplenomegaly as part of systemic ANKL.
  downstream:
  - target: Lymphadenopathy
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    description: >-
      Lymphadenopathy was reported in the prolonged-prodrome subset; the route
      from systemic disease to nodal enlargement is not resolved.
    evidence:
    - reference: PMID:29263371
      reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        They manifested infectious mononucleosis (IM)-like symptoms (including
        fever, lymphocytosis or mononucleosis, lymphadenopathy, and
        hepatosplenomegaly) for more than 90 days (median: 115 days, range:
        90–450 days), prior to the fulminant onset (Table 1).
      explanation: >-
        The cohort supports lymphadenopathy in the proposed prolonged-prodrome
        subset, with edge directness left unknown.
  - target: Hepatosplenomegaly
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    description: >-
      Systemic ANKL involvement commonly includes concurrent liver and spleen
      enlargement.
    evidence:
    - reference: DOI:10.3390/cancers12102900
      reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Patients commonly present acutely with fever, constitutional symptoms,
        hepatosplenomegaly, and often disseminated intravascular coagulation or
        hemophagocytic syndrome.
      explanation: >-
        The review directly names hepatosplenomegaly as a common ANKL
        presentation feature, but not a direct mechanistic edge.
  - target: Elevated Transaminases
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    description: >-
      Transaminitis accompanies liver impairment in ANKL; directness from tissue
      involvement is not established by the cohort.
    evidence:
    - reference: PMID:29263371
      reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Alleviated hyperferritinemia (P < 0.001), transaminitis (ALT, P = 0.009),
        and hypofibrinogenemia (P = 0.038), suggesting alleviated hemophagocytic
        lymphohistiocytosis (HLH), liver impairment, and coagulopathy, were also
        noted at diagnosis in these patients (Table 1 and Supplementary Table S3).
      explanation: >-
        The cohort supports transaminitis and liver impairment in the proposed
        prolonged-prodrome subset.
  - target: Thrombocytopenia
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    description: >-
      Severe thrombocytopenia occurs in ANKL, while marrow, inflammatory, and
      consumptive contributions are not separated by the outcome analysis.
    evidence:
    - reference: PMID:29263371
      reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Univariate analysis revealed the following clinical factors to be
        significantly associated with shorter survival: thrombocytopenia (<30 ×
        109/l), elevated serum LDH level (>800 IU/l), hypoalbuminemia (<35 g/l),
        hyperferritinemia (>1500 IU/l), classic ANKL, treatment without
        L-asparagine-based chemotherapy, or allo-HSCT (Supplementary Table S6).
      explanation: >-
        The cohort supports severe thrombocytopenia as a prognostic clinical
        finding; causal directness remains unknown.
  - target: Pancytopenia
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    description: >-
      Cytopenias, including pancytopenia, can accompany the ANKL leukemic and
      HLH-like inflammatory presentation.
    evidence:
    - reference: DOI:10.1155/crh/7796972
      reference_title: "Aggressive Natural Killer Cell Leukemia: A Rare and Rapidly Progressive Hematologic Malignancy—Case Report and Literature Review"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We present a case of a 71‐year‐old Caucasian male who developed fever,
        altered mental status, hepatosplenomegaly, pancytopenia, and
        hemophagocytic lymphohistiocytosis (HLH) and who was ultimately diagnosed
        with ANKL.
      explanation: >-
        The case report directly supports pancytopenia within an ANKL
        presentation, while the exact intermediate route remains variable.
- name: HLH-Like Hyperinflammation
  description: >-
    ANKL can present with a hemophagocytic lymphohistiocytosis-like systemic
    inflammatory syndrome. This node represents the inflammatory context, not
    histologic hemophagocytosis and not a claim that every case meets HLH criteria.
  cell_types:
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  locations:
  - preferred_term: blood
    term:
      id: UBERON:0000178
      label: blood
  biological_processes:
  - preferred_term: cytokine-mediated signaling pathway
    modifier: INCREASED
    term:
      id: GO:0019221
      label: cytokine-mediated signaling pathway
  evidence:
  - reference: DOI:10.3389/frhem.2024.1413794
    reference_title: "Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Aggressive natural killer cell leukemia (ANKL) is a rare, aggressive
      hematologic malignancy which often presents as fulminant Epstein-Barr
      virus (EBV)- driven hemophagocytic lymphohistiocytosis (HLH).
    explanation: >-
      The report supports an HLH-like inflammatory presentation in EBV-positive
      ANKL.
  downstream:
  - target: Fever
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    - ebv_positive_superimposed_branch
    description: >-
      Fever accompanies the acute inflammatory presentation; the evidence does
      not isolate a direct route from this modeled node.
    evidence:
    - reference: DOI:10.3390/cancers12102900
      reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Patients commonly present acutely with fever, constitutional symptoms,
        hepatosplenomegaly, and often disseminated intravascular coagulation or
        hemophagocytic syndrome.
      explanation: >-
        The review supports co-occurrence of fever and hemophagocytic syndrome
        in acute ANKL.
  - target: Increased Ferritin
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    - ebv_positive_superimposed_branch
    description: >-
      Hyperferritinemia is a clinical correlate of the HLH-like inflammatory
      state, with causal directness unresolved.
    evidence:
    - reference: PMID:29263371
      reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Alleviated hyperferritinemia (P < 0.001), transaminitis (ALT, P = 0.009),
        and hypofibrinogenemia (P = 0.038), suggesting alleviated hemophagocytic
        lymphohistiocytosis (HLH), liver impairment, and coagulopathy, were also
        noted at diagnosis in these patients (Table 1 and Supplementary Table S3).
      explanation: >-
        The subgroup comparison associates ferritin burden with the HLH-like
        clinical state.
  - target: Coagulation Dysregulation
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    - ebv_positive_superimposed_branch
    description: >-
      HLH-like inflammation and coagulopathy co-occur in ANKL, but the causal
      intermediates and directness are not resolved.
    evidence:
    - reference: PMID:29263371
      reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Alleviated hyperferritinemia (P < 0.001), transaminitis (ALT, P = 0.009),
        and hypofibrinogenemia (P = 0.038), suggesting alleviated hemophagocytic
        lymphohistiocytosis (HLH), liver impairment, and coagulopathy, were also
        noted at diagnosis in these patients (Table 1 and Supplementary Table S3).
      explanation: >-
        The cohort supports linked inflammatory and coagulation abnormalities
        while not establishing a direct mechanism.
- name: Coagulation Dysregulation
  description: >-
    ANKL can produce a coagulopathic presentation that includes
    hypofibrinogenemia and disseminated intravascular coagulation.
  locations:
  - preferred_term: blood
    term:
      id: UBERON:0000178
      label: blood
  biological_processes:
  - preferred_term: coagulation
    modifier: ABNORMAL
    term:
      id: GO:0050817
      label: coagulation
  evidence:
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Patients commonly present acutely with fever, constitutional symptoms,
      hepatosplenomegaly, and often disseminated intravascular coagulation or
      hemophagocytic syndrome.
    explanation: >-
      The review supports DIC as part of the acute ANKL presentation.
  downstream:
  - target: Disseminated Intravascular Coagulation
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    - ebv_positive_superimposed_branch
    description: >-
      DIC is the overt clinical manifestation of the modeled coagulopathy, but
      the cited clinical review does not prove a direct edge.
    evidence:
    - reference: DOI:10.3390/cancers12102900
      reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Patients commonly present acutely with fever, constitutional symptoms,
        hepatosplenomegaly, and often disseminated intravascular coagulation or
        hemophagocytic syndrome.
      explanation: >-
        The review directly reports DIC in the acute presentation while edge
        directness remains unknown.
  - target: Hypofibrinogenemia
    causal_link_type: UNKNOWN
    hypothesis_groups:
    - multihit_nk_neoplasia_model
    - ebv_positive_superimposed_branch
    description: >-
      Low fibrinogen is a reported component of ANKL-associated coagulopathy.
    evidence:
    - reference: PMID:29263371
      reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Alleviated hyperferritinemia (P < 0.001), transaminitis (ALT, P = 0.009),
        and hypofibrinogenemia (P = 0.038), suggesting alleviated hemophagocytic
        lymphohistiocytosis (HLH), liver impairment, and coagulopathy, were also
        noted at diagnosis in these patients (Table 1 and Supplementary Table S3).
      explanation: >-
        The cohort identifies hypofibrinogenemia as a coagulation abnormality in
        ANKL.
histopathology:
- name: Interstitial and Sinusoidal Bone Marrow Involvement
  finding_term:
    preferred_term: Interstitial and sinusoidal bone marrow involvement
    term:
      id: NCIT:C8288
      label: Bone Marrow Involvement
  diagnostic: true
  description: >-
    Bone marrow involvement by ANKL can show interstitial or sinusoidal
    infiltration patterns, supporting a marrow-based leukemic presentation when
    interpreted with NK-cell immunophenotyping.
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Two distinct patterns of bone marrow involvement were identified:
      interstitial and sinusoidal.
    explanation: >-
      This clinicopathologic series supports the marrow infiltration patterns as
      a histopathologic feature of ANKL.
phenotypes:
- category: Constitutional
  name: Fever
  description: >-
    Acute fever is a common feature of the fulminant systemic presentation.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Patients commonly present acutely with fever, constitutional symptoms,
      hepatosplenomegaly, and often disseminated intravascular coagulation or
      hemophagocytic syndrome.
    explanation: >-
      The review explicitly includes fever in the common acute presentation.
- category: Organomegaly
  name: Hepatosplenomegaly
  description: >-
    Concurrent liver and spleen enlargement reflects reticuloendothelial organ
    involvement in the systemic leukemic process.
  phenotype_term:
    preferred_term: Hepatosplenomegaly
    term:
      id: HP:0001433
      label: Hepatosplenomegaly
  evidence:
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Patients commonly present acutely with fever, constitutional symptoms,
      hepatosplenomegaly, and often disseminated intravascular coagulation or
      hemophagocytic syndrome.
    explanation: >-
      The review abstract directly names hepatosplenomegaly as a common ANKL
      presentation feature.
- category: Hematologic
  name: Disseminated Intravascular Coagulation
  description: >-
    DIC is a life-threatening coagulopathy reported in the acute ANKL
    presentation.
  phenotype_term:
    preferred_term: Disseminated intravascular coagulation
    term:
      id: HP:0005521
      label: Disseminated intravascular coagulation
  evidence:
  - reference: DOI:10.3390/cancers12102900
    reference_title: "Aggressive NK Cell Leukemia: Current State of the Art"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Patients commonly present acutely with fever, constitutional symptoms,
      hepatosplenomegaly, and often disseminated intravascular coagulation or
      hemophagocytic syndrome.
    explanation: >-
      The abstract directly supports DIC as a feature of the acute ANKL
      presentation.
- category: Laboratory
  name: Increased Ferritin
  description: >-
    Hyperferritinemia accompanies the HLH-like inflammatory presentation and
    was associated with shorter survival in univariate analysis of a retrospective
    cohort.
  phenotype_term:
    preferred_term: Increased circulating ferritin concentration
    term:
      id: HP:0003281
      label: Increased circulating ferritin concentration
  evidence:
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Alleviated hyperferritinemia (P < 0.001), transaminitis (ALT, P = 0.009),
      and hypofibrinogenemia (P = 0.038), suggesting alleviated hemophagocytic
      lymphohistiocytosis (HLH), liver impairment, and coagulopathy, were also
      noted at diagnosis in these patients (Table 1 and Supplementary Table S3).
    explanation: >-
      The subgroup comparison directly documents hyperferritinemia in ANKL.
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Univariate analysis revealed the following clinical factors to be
      significantly associated with shorter survival: thrombocytopenia
      (<30 × 109/l), elevated serum LDH level (>800 IU/l), hypoalbuminemia
      (<35 g/l), hyperferritinemia (>1500 IU/l), classic ANKL, treatment without
      L-asparagine-based chemotherapy, or allo-HSCT (Supplementary Table S6).
    explanation: >-
      The cohort's univariate analysis directly associates hyperferritinemia
      above 1500 IU/l with shorter survival.
- category: Hematologic
  name: Pancytopenia
  description: >-
    Cytopenias, including pancytopenia, can accompany the acute leukemic and
    HLH-like presentation of ANKL.
  phenotype_term:
    preferred_term: Pancytopenia
    term:
      id: HP:0001876
      label: Pancytopenia
  evidence:
  - reference: DOI:10.1155/crh/7796972
    reference_title: "Aggressive Natural Killer Cell Leukemia: A Rare and Rapidly Progressive Hematologic Malignancy—Case Report and Literature Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present a case of a 71‐year‐old Caucasian male who developed fever,
      altered mental status, hepatosplenomegaly, pancytopenia, and
      hemophagocytic lymphohistiocytosis (HLH) and who was ultimately diagnosed
      with ANKL.
    explanation: >-
      The case report directly supports pancytopenia as part of an ANKL
      presentation.
- category: Lymphatic
  name: Lymphadenopathy
  description: >-
    Lymphadenopathy was reported among the infectious mononucleosis-like
    manifestations in the cohort-proposed prolonged-prodrome subset.
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
  evidence:
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They manifested infectious mononucleosis (IM)-like symptoms (including
      fever, lymphocytosis or mononucleosis, lymphadenopathy, and
      hepatosplenomegaly) for more than 90 days (median: 115 days, range:
      90–450 days), prior to the fulminant onset (Table 1).
    explanation: >-
      The cohort supports lymphadenopathy in the prolonged-prodrome subset.
- category: Hematologic
  name: Thrombocytopenia
  description: >-
    Severe thrombocytopenia was associated with shorter survival in a
    retrospective ANKL cohort.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  evidence:
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Univariate analysis revealed the following clinical factors to be
      significantly associated with shorter survival: thrombocytopenia (<30 ×
      109/l), elevated serum LDH level (>800 IU/l), hypoalbuminemia (<35 g/l),
      hyperferritinemia (>1500 IU/l), classic ANKL, treatment without
      L-asparagine-based chemotherapy, or allo-HSCT (Supplementary Table S6).
    explanation: >-
      The cohort directly identifies severe thrombocytopenia as a prognostic
      finding.
- category: Hematologic
  name: Hypofibrinogenemia
  description: >-
    Reduced fibrinogen is part of the coagulopathic presentation documented in
    ANKL cohorts.
  phenotype_term:
    preferred_term: Hypofibrinogenemia
    term:
      id: HP:0011900
      label: Hypofibrinogenemia
  evidence:
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Alleviated hyperferritinemia (P < 0.001), transaminitis (ALT, P = 0.009),
      and hypofibrinogenemia (P = 0.038), suggesting alleviated hemophagocytic
      lymphohistiocytosis (HLH), liver impairment, and coagulopathy, were also
      noted at diagnosis in these patients (Table 1 and Supplementary Table S3).
    explanation: >-
      The cohort directly documents hypofibrinogenemia at diagnosis.
- category: Laboratory
  name: Elevated Transaminases
  description: >-
    Transaminitis reflects liver impairment in the systemic ANKL presentation.
  phenotype_term:
    preferred_term: Elevated circulating hepatic transaminase concentration
    term:
      id: HP:0002910
      label: Elevated circulating hepatic transaminase concentration
  evidence:
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Alleviated hyperferritinemia (P < 0.001), transaminitis (ALT, P = 0.009),
      and hypofibrinogenemia (P = 0.038), suggesting alleviated hemophagocytic
      lymphohistiocytosis (HLH), liver impairment, and coagulopathy, were also
      noted at diagnosis in these patients (Table 1 and Supplementary Table S3).
    explanation: >-
      The cohort directly documents transaminitis and interprets it as liver
      impairment.
genetic:
- name: STAT3
  gene_term:
    preferred_term: STAT3
    term:
      id: hgnc:11364
      label: STAT3
  association: Recurrent activating somatic mutation and JAK-STAT pathway activation in ANKL
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  evidence:
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We study 14 ANKL patients using whole-exome sequencing (WES) and identify
      mutations inSTAT3(21%) and RAS-MAPK pathway genes (21%) as well as
      inDDX3X(29%) and epigenetic modifiers (50%).
    explanation: >-
      Whole-exome sequencing of human ANKL tumors identified recurrent STAT3
      mutations.
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In total, we identi ﬁed several copy-number alterations (Supplementary
      Fig. 3) and 419 nonsynonymous somatic muta- tion candidates in
      tumor-control pairs and 529 in tumor-only samples
    explanation: >-
      The sequencing workflow explicitly identifies the analyzed alterations as
      somatic mutation candidates.
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Markedly, 2/3 discovered STAT3 mutations have previously been reported as
      activating 12,18, and they localized to exons 20 and 21 encoding the Src
      homology 2 (SH2) domain mediating the dimerization and activation of STAT3
      (Fig. 2a).
    explanation: >-
      The cohort directly identifies most observed STAT3 variants as previously
      reported activating mutations in the SH2 domain.
- name: TP53
  gene_term:
    preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  association: Recurrent TP53 alteration and p53 overexpression in ANKL
  relationship_type: UNKNOWN
  variant_origin: UNKNOWN
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2
      mutations were each detected in 2 of 6 cases.
    explanation: >-
      This clinicopathologic series supports recurrent TP53 mutations in ANKL.
- name: DDX3X
  gene_term:
    preferred_term: DDX3X
    term:
      id: hgnc:2745
      label: DDX3X
  association: Recurrent somatic mutation in ANKL genomic profiling
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  evidence:
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      DDX3X, BCOR, and STAT3 were identiﬁed in ANKL as recurrent by both the
      MutSigCV and Oncodrive-fm algorithms
    explanation: >-
      Two driver-discovery algorithms independently identified DDX3X as
      recurrent in ANKL.
- name: ASXL1
  gene_term:
    preferred_term: ASXL1
    term:
      id: hgnc:18318
      label: ASXL1
  association: Epigenetic modifier mutation in ANKL
  relationship_type: UNKNOWN
  variant_origin: UNKNOWN
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2
      mutations were each detected in 2 of 6 cases.
    explanation: >-
      This clinicopathologic series supports ASXL1 mutation as a recurrent
      epigenetic modifier lesion in ANKL.
- name: TET2
  gene_term:
    preferred_term: TET2
    term:
      id: hgnc:25941
      label: TET2
  association: Epigenetic modifier mutation in ANKL
  relationship_type: UNKNOWN
  variant_origin: UNKNOWN
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TP53 mutations were detected in 3 of 6 cases, whereas ASXL1 and TET2
      mutations were each detected in 2 of 6 cases.
    explanation: >-
      This clinicopathologic series supports TET2 mutation as a recurrent
      epigenetic modifier lesion in ANKL.
progression:
- phase: Cohort-Proposed Prolonged Prodromal Course in a Subset
  duration: more than 90 days in the reported cohort
  notes: >-
    A retrospective Han Chinese cohort described an infectious
    mononucleosis-like prodrome in 18 of 113 patients and proposed, rather than
    established, a “subacute ANKL” clinical subtype. This entry records a
    cohort-specific course pattern and is not modeled as a WHO/ICC subtype.
  evidence:
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Intriguingly, a subacute clinical course was demonstrated in 18 ANKL
      patients (15.93%, 18/113).
    explanation: >-
      The cohort quantifies the proposed prolonged-prodrome subset.
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All these data suggested that patients with prolonged prodromal phases,
      whom we define here as “subacute ANKL”, may represent a clinical subtype
      of ANKL which differed from the others, whom we define here as “classic
      ANKL”.
    explanation: >-
      The authors explicitly frame the classification as a proposal.
- phase: Fulminant Presentation and Early Mortality
  duration: often weeks to months
  notes: >-
    ANKL remains highly lethal. Median survival of two months and 55 days came
    from a 12-case clinicopathologic series and a 2003–2016 Han Chinese cohort,
    respectively, and should not be treated as timeless universal estimates.
    The ANKL22 study, published in 2026, analyzed 108 evaluable patients
    diagnosed during 2000–2021 and reported median overall survival of 5.5
    months and two-year survival of 18.7%, with better outcomes associated with
    SMILE and allogeneic HSCT.
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients had very poor outcomes despite intensive chemotherapy, with a
      median survival of 2 months.
    explanation: >-
      The 12-case series directly supports very poor prognosis and short median
      survival.
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median OS was only 55 days (Supplementary Tables S2) and 1-year
      survival rate was only 4.42% (5/113; Supplementary Fig. S1B), which
      indicated a dismal outcome of ANKL.
    explanation: >-
      The historical 113-patient cohort supports very poor survival in its
      specific population and treatment era.
  - reference: PMID:41501503
    reference_title: "Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We retrospectively collected 126 ANKL patients diagnosed between 2000 and
      2021 from 71 institutes; 108 were evaluable for analysis to characterize
      the recent advances.
    explanation: >-
      The study dates the diagnosis interval and identifies the 108-patient
      evaluable cohort.
  - reference: PMID:41501503
    reference_title: "Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Median overall survival (OS) was 5.5 months, with a 2-year OS of 18.7%.
    explanation: >-
      The 2026 multicenter cohort provides a treatment-era prognosis estimate.
  - reference: PMID:41501503
    reference_title: "Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients treated with SMILE had significantly better OS than others
      (2-year OS 30.1% vs. 7.0%; P < 0.001). Prognosis further improved with
      allogeneic hematopoietic stem cell transplantation (HSCT) (2-year OS
      37.2% vs 3.5%; P < 0.001).
    explanation: >-
      Cohort comparisons support association of SMILE and allogeneic HSCT with
      improved survival in the treatment-era cohort without establishing
      randomized treatment effects.
diagnosis:
- name: Integrated Clinicopathologic Assessment
  description: >-
    ANKL diagnosis integrates the systemic clinical course, blood and marrow
    morphology, and NK-cell immunophenotype while excluding other mature
    T/NK-cell neoplasms and reactive HLH. EBV studies and molecular findings may
    provide adjunctive context; no defining molecular lesion is required.
  results: >-
    A systemic leukemic NK-cell neoplasm supported by concordant morphology and
    immunophenotype favors ANKL; EBV positivity refines the disease context but
    is not required.
  evidence:
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      with a surface immunophenotype characteristic of NK cells
      (CD2+CD3−CD56+), systemic involvement including bone marrow
    explanation: >-
      The study states the NK-cell immunophenotype and systemic marrow
      involvement used among the ANKL-specific diagnostic requirements for its
      human cohort.
  - reference: PMID:37870698
    reference_title: Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      WHO-HAEM5 and ICC share basic concepts in classification of T/NK-cell
      neoplasms, emphasizing integration of clinical presentation, pathology,
      immunophenotype, and genetics.
    explanation: >-
      The current classification review supports an integrated diagnostic
      approach for mature T/NK-cell neoplasms.
- name: NK-Cell Flow Cytometry and Immunophenotyping
  description: >-
    Diagnosis requires identifying an abnormal NK-cell population and excluding
    T-cell lineage by immunophenotyping. A typical pattern is CD56/CD94-positive
    and surface CD3/CD5/CD57-negative.
  diagnosis_term:
    preferred_term: flow cytometry immunophenotyping
    term:
      id: NCIT:C113003
      label: Immunological Flow Cytometry
  results: >-
    An atypical CD3-/CD56+ or CD56+/CD94+ NK-cell population in marrow or blood
    supports ANKL in the appropriate clinicopathologic context.
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The neoplastic cells were positive for CD56 and CD94, and negative for
      surface CD3, CD5, and CD57 in all cases assessed.
    explanation: >-
      This case series supports the core diagnostic immunophenotype.
  - reference: DOI:10.3389/frhem.2024.1413794
    reference_title: "Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      bone marrow biopsy demonstrated an atypical CD3-/CD56+ natural killer
      (NK) cell population with diminished CD7 expression consistent with EBV+
      ANKL.
    explanation: >-
      The case report demonstrates diagnostic recognition of ANKL by marrow
      biopsy and NK-cell immunophenotyping.
- name: EBER In Situ Hybridization
  description: >-
    EBER testing identifies the frequent but non-universal EBV-positive branch
    of ANKL.
  diagnosis_term:
    preferred_term: EBER in situ hybridization
    term:
      id: NCIT:C138177
      label: Epstein-Barr Encoding Region in situ Hybridization
  results: >-
    EBER positivity supports EBV-positive ANKL; a negative result does not exclude
    ANKL because not every case in the cited series was EBER-positive.
  evidence:
  - reference: DOI:10.1097/pas.0000000000001518
    reference_title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They were also positive for CD2 (10/12), c-MYC (6/8), BCL2 (6/8), CD16
      (5/7), EBER (9/12), CD7 (6/11), pSTAT3Tyr705 (3/8), CD8 (2/6), PD-L1
      (2/8), CD4 (2/11), CD8 (2/6), and CD158 (1/5).
    explanation: >-
      The 12-case series reports EBER positivity in nine of twelve cases,
      demonstrating frequent but non-universal positivity.
treatments:
- name: L-Asparaginase-Containing Chemotherapy (Including SMILE)
  action_category: THERAPEUTIC
  description: >-
    There is no universally standardized initial regimen. Retrospective cohorts
    support L-asparaginase-containing induction, with a recent cohort reporting
    higher response and survival with SMILE than with comparator regimens.
    Selection remains individualized because the evidence is non-randomized and
    ANKL is rare.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
    therapeutic_agent:
    - preferred_term: Asparaginase
      term:
        id: NCIT:C286
        label: Asparaginase
  target_mechanisms:
  - target: Malignant NK-Cell Survival and Expansion
    treatment_effect: INHIBITS
    description: >-
      Cytotoxic L-asparaginase-containing induction is intended to reduce the
      malignant NK-cell burden.
    evidence:
    - reference: PMID:41501503
      reference_title: "Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The first-line regimens included SMILE (n = 38, 42%), CHOP(-like) (n = 26, 29%), DeVIC (n = 15, 17%), and other L-asparaginase-containing regimens (n = 8, 9%), with the overall response rates of 66%, 31%, 33%, and 50%, respectively."  # codespell:ignore-line
      explanation: >-
        Clinical response rates support reduction of disease burden by
        L-asparaginase-containing regimens.
  evidence:
  - reference: PMID:41501503
    reference_title: "Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients treated with SMILE had significantly better OS than others (2-year
      OS 30.1% vs. 7.0%; P < 0.001).
    explanation: >-
      The 2026 retrospective multicenter cohort associates SMILE with improved
      survival.
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Further subgroup analysis for patients receiving chemotherapy alone
      revealed significant OS benefit achieved only in patients treated with
      L-ASPA-based chemotherapy (n = 19, P = 0.008; Supplementary Fig. S4B).
    explanation: >-
      An earlier retrospective cohort also associated L-asparaginase-based
      chemotherapy with survival benefit.
- name: Allogeneic Hematopoietic Stem Cell Transplantation
  therapeutic_modality: CELL_THERAPY
  action_category: THERAPEUTIC
  description: >-
    Allogeneic hematopoietic stem cell transplantation is considered as
    consolidation for eligible patients who respond to induction therapy.
    Retrospective survival associations support this strategy, but do not define
    a simple direct pathophysiology target.
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  evidence:
  - reference: PMID:41501503
    reference_title: "Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Prognosis further improved with allogeneic hematopoietic stem cell
      transplantation (HSCT) (2-year OS 37.2% vs 3.5%; P < 0.001).
    explanation: >-
      The 2026 retrospective cohort associates allogeneic HSCT with improved
      two-year survival.
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients receiving allo-HSCT exhibited significantly superior survivals
      when compared to the others without allo-HSCT (P < 0.001).
    explanation: >-
      The earlier cohort independently supports a survival association with
      allogeneic transplantation.
- name: Preclinical JAK Inhibition
  action_category: THERAPEUTIC
  description: >-
    JAK inhibition is an investigational, preclinical strategy motivated by
    recurrent JAK-STAT alterations and NK-lineage drug sensitivity. The cited
    evidence does not establish clinical efficacy in ANKL.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ruxolitinib
      term:
        id: CHEBI:66919
        label: ruxolitinib
  target_mechanisms:
  - target: JAK-STAT Pathway Activation
    treatment_effect: INHIBITS
    description: >-
      JAK inhibition is intended to suppress recurrent JAK-STAT signaling
      activity in NK-cell malignancies.
    evidence:
    - reference: DOI:10.1038/s41467-018-03987-2
      reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Focusing on targeted agents, we found the JAK inhibitor ruxolitinib and
        the BCL2 family inhibitor navitoclax to be highly effective across the
        cell lines (Fig. 3a).
      explanation: >-
        Drug profiling supports ruxolitinib-mediated JAK inhibition in NK-lineage
        models, not established ANKL efficacy.
  evidence:
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Focusing on targeted agents, we found the JAK inhibitor ruxolitinib and
      the BCL2 family inhibitor navitoclax to be highly effective across the cell
      lines (Fig. 3a).
    explanation: >-
      In vitro drug profiling supports a ruxolitinib treatment rationale, but
      not an established clinical standard for ANKL.
clinical_trials:
- name: NCT03719105
  status: RECRUITING
  description: >-
    Recruiting early-phase I pilot chemoimmunotherapy study using modified
    SMILE-style induction for advanced NK lymphoma/leukemia followed by
    allogeneic stem cell transplant for responders.
  review_notes: >-
    ClinicalTrials.gov phase and recruitment status checked 2026-07-17. The
    registry reports EARLY_PHASE1, which has no exact schema mapping, and status
    RECRUITING; `phase` is therefore omitted.
  evidence:
  - reference: clinicaltrials:NCT03719105
    reference_title: Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and
      etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in
      children, adolescents, and young adults with advanced stage NK lymphoma
      and leukemia
    explanation: >-
      The trial summary directly describes the ANKL-relevant induction regimen
      for advanced NK lymphoma/leukemia.
- name: NCT03623087
  phase: PHASE_III
  status: UNKNOWN
  description: >-
    Phase III SIMPLE chemotherapy study for NK/T-cell malignancies, derived from
    a PIGLETS protocol used in extranodal NK/T-cell lymphoma and aggressive NK
    leukemia. The registry currently reports unknown status.
  review_notes: >-
    ClinicalTrials.gov phase and status checked 2026-07-17. The registry reports
    PHASE3 and UNKNOWN and has not verified recruitment status since 2018.
  evidence:
  - reference: clinicaltrials:NCT03623087
    reference_title: "Combination Chemotherapy Using Cisplatin, Gemcitabine, Ifosfamide, Etoposide, L-asparaginase and Dexamethasone (SIMPLE) for Newly Diagnosed and Relapsed/Refractory NK/T Cell Malignancies"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NK malignancies consist of two different clinical entities, extranodal
      NK/T cell lymphoma and aggressive NK leukaemia.
    explanation: >-
      The trial summary explicitly includes aggressive NK leukemia in the NK
      malignancy population targeted by the chemotherapy study.
- name: NCT05863234
  status: RECRUITING
  description: >-
    Recruiting phase I/II dose-escalation clinical trial evaluating repeated
    continuous intravenous PPMX-T003 in aggressive NK-cell leukemia.
  review_notes: >-
    ClinicalTrials.gov status checked 2026-07-17 and reported RECRUITING, with
    last verification in 2025-04. The registry reports both PHASE1 and PHASE2;
    `phase` is omitted because the schema has no combined phase I/II value.
  evidence:
  - reference: clinicaltrials:NCT05863234
    reference_title: Multicenter, Open-label, Dose-escalation Phase I/II Study to Evaluate the Tolerability, Safety, Efficacy and Pharmacokinetics of Repeated Continuous Intravenous PPMX-T003 in Patients With Aggressive NK Cell Leukaemia (ANKL) (Physician-initiated Clinical Trial)
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is Phase I/II Dose-Escalation Study to evaluate the tolerability,
      safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell
      leukemia.
    explanation: >-
      The trial summary directly supports an ANKL-specific PPMX-T003 clinical
      trial.
differential_diagnoses:
- name: EBV-Driven Hemophagocytic Lymphohistiocytosis Without Neoplasia
  description: >-
    EBV-HLH can be the initial presentation of ANKL, but EBV-HLH without a
    malignant NK/T-cell population is a key differential diagnosis during early
    evaluation.
  distinguishing_features:
  - Detection of an atypical CD3-negative, CD56-positive NK-cell population in marrow supports ANKL rather than isolated EBV-HLH.
  evidence:
  - reference: DOI:10.3389/frhem.2024.1413794
    reference_title: "Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This case highlights the diagnostic challenges of ANKL given the lack of
      standardized diagnostic criteria, the importance of considering T/NK cell
      malignancies in the differential diagnosis of EBV-HLH, and adds to the
      literature on this rare disease.
    explanation: >-
      This case report explicitly states that T/NK malignancies must be
      considered in the differential diagnosis of EBV-HLH.
  - reference: DOI:10.3389/frhem.2024.1413794
    reference_title: "Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      bone marrow biopsy demonstrated an atypical CD3-/CD56+ natural killer
      (NK) cell population with diminished CD7 expression consistent with EBV+
      ANKL.
    explanation: >-
      The case directly supports identifying an aberrant NK-cell population in
      marrow when ANKL presents as EBV-HLH.
- name: Extranodal NK/T-Cell Lymphoma
  description: >-
    Extranodal NK/T-cell lymphoma is another EBV-associated NK/T malignancy with
    overlapping immunophenotypic, molecular, and clinical features. ANKL should
    not be modeled simply as a more advanced leukemic form of extranodal NK/T-cell
    lymphoma; integrated anatomic and clinicopathologic assessment is required.
  distinguishing_features:
  - A systemic leukemic blood-and-marrow presentation supports ANKL, but no single recurrent mutation reliably resolves the boundary.
  evidence:
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      arguing against the hypothesis that ANKL would represent a more advanced
      form of NKTCL.
    explanation: >-
      Comparative genomic analysis argues against treating ANKL as merely an
      advanced form of extranodal NK/T-cell lymphoma.
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      ANKL diagnosis was made according to the WHO classi ﬁcation, with a
      surface immunophenotype characteristic of NK cells (CD2+CD3−CD56+),
      systemic involvement including bone marrow and/or per- ipheral blood and
      an aggressive clinical course as minimum requirements for diagnosis.
    explanation: >-
      The study's WHO-based inclusion criteria support the systemic blood or
      marrow presentation used to distinguish ANKL.
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      closely related extranodal NK/T-cell lymphoma, nasal type (NKTCL), an
      extranodal lymphoma commonly presenting in the nasal cavity
    explanation: >-
      The comparative discussion supports the characteristic extranodal nasal
      presentation of NKTCL.
- name: Chronic NK-Cell Lymphoproliferative Disorder (NK-LGLL/CLPD-NK)
  description: >-
    Chronic NK-cell lymphoproliferative disorder is a distinct, relatively
    indolent NK-cell proliferation that should not be conflated with fulminant
    ANKL.
  distinguishing_features:
  - A chronic indolent NK-cell lymphocytosis favors NK-LGLL/CLPD-NK; fulminant systemic leukemia with organ involvement and HLH-like inflammation favors ANKL.
  evidence:
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Gain-of-function STAT3 mutations have also been previously described in
      diseases of varying aggressiveness, such as NKTCL and the relatively
      indolent T-LGLL and CLPD-NK
    explanation: >-
      The study explicitly treats T-LGLL/CLPD-NK as relatively indolent
      comparators rather than synonyms for fulminant ANKL.
- name: Chronic Active EBV Disease and Other EBV-Positive T/NK Lymphoproliferative Disorders
  description: >-
    Chronic active EBV disease and related EBV-positive T/NK lymphoproliferative
    disorders can precede or mimic ANKL, particularly during prolonged systemic
    symptoms. Age, tempo, morphology, immunophenotype, and demonstration of a
    malignant NK-cell population must be integrated.
  distinguishing_features:
  - A chronic EBV-associated course without a demonstrable aggressive leukemic NK-cell neoplasm favors chronic active EBV disease; abrupt fulminant systemic leukemia favors ANKL.
  evidence:
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CAEBV is an indolent disease primarily affecting children and young adults4.
      While ANKL usually presents a relatively acute disease mainly occurs in
      the middle-aged population, even though a subacute clinical course may
      manifest in a subset of patients.
    explanation: >-
      The cohort discussion contrasts the usual age and tempo of CAEBV and ANKL
      while acknowledging a prolonged-course ANKL subset.
discussions:
- discussion_id: ankl_proposed_subacute_course_reproducibility
  prompt: >-
    Does the prolonged infectious mononucleosis-like prodrome reported in one
    retrospective cohort define a reproducible biological subgroup, or a
    cohort-specific clinical-course pattern within ANKL?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - progression#Cohort-Proposed Prolonged Prodromal Course in a Subset
  rationale: >-
    Treating the proposed “subacute ANKL” course as an established subtype would
    overstate evidence from 18 of 113 Han Chinese patients and could obscure
    differences among later cohorts and classification systems.
  evidence:
  - reference: PMID:29263371
    reference_title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All these data suggested that patients with prolonged prodromal phases,
      whom we define here as “subacute ANKL”, may represent a clinical subtype
      of ANKL which differed from the others, whom we define here as “classic
      ANKL”.
    explanation: >-
      The authors explicitly present the subgroup as a proposed interpretation.
- discussion_id: ankl_ebv_positive_negative_mechanistic_relationship
  prompt: >-
    Which mechanisms distinguish EBV-positive and EBV-negative ANKL, and which
    molecular lesions are shared across both contexts?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#EBV-Positive Neoplastic Context
  - pathophysiology#JAK-STAT Pathway Activation
  - pathophysiology#DDX3X Alteration
  rationale: >-
    EBV is frequent but not obligatory, and recurrent STAT3/DDX3X lesions occur
    in EBV-negative disease. Resolving shared versus EBV-specific dependencies is
    necessary before assigning EBV an initiating causal role.
  evidence:
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      mutations recurrent among our EBV-positive cases, such as STAT3 and DDX3X,
      have also been reported to occur in EBV- negative cases
    explanation: >-
      Shared recurrent lesions motivate direct comparison of EBV-positive and
      EBV-negative disease mechanisms.
- discussion_id: ankl_nk_lgll_nktcl_boundary
  prompt: >-
    How should ANKL nomenclature and diagnostic boundaries be reconciled with
    indolent NK-LGLL/CLPD-NK and extranodal NK/T-cell lymphoma?
  kind: INTERPRETATION
  status: OPEN
  attaches_to:
  - pathophysiology#Malignant NK-Cell Survival and Expansion
  rationale: >-
    A historical MONDO synonym can be read as the distinct indolent NK-LGLL
    entity, while comparative genomics argues against treating ANKL as merely an
    advanced extranodal NK/T-cell lymphoma. Integrated classification should
    preserve these clinical boundaries.
  evidence:
  - reference: DOI:10.1038/s41467-018-03987-2
    reference_title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Gain-of-function STAT3 mutations have also been previously described in
      diseases of varying aggressiveness, such as NKTCL and the relatively
      indolent T-LGLL and CLPD-NK
    explanation: >-
      The comparative discussion supports keeping indolent LGL disorders
      distinct from ANKL despite shared molecular features.
references:
- reference: DOI:10.3390/cancers12102900
  title: "Aggressive NK Cell Leukemia: Current State of the Art"
  findings: []
- reference: DOI:10.3389/frhem.2024.1413794
  title: "Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent"
  findings: []
- reference: DOI:10.1097/pas.0000000000001518
  title: Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia
  findings: []
- reference: DOI:10.1038/s41467-018-03987-2
  title: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
  findings: []
- reference: PMID:29263371
  title: "Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes."
  findings: []
- reference: DOI:10.1155/crh/7796972
  title: "Aggressive Natural Killer Cell Leukemia: A Rare and Rapidly Progressive Hematologic Malignancy—Case Report and Literature Review"
  findings: []
- reference: PMID:41501503
  title: "Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study."
  findings: []
- reference: PMID:37870698
  title: Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders.
  findings: []
- reference: clinicaltrials:NCT03623087
  title: "Combination Chemotherapy Using Cisplatin, Gemcitabine, Ifosfamide, Etoposide, L-asparaginase and Dexamethasone (SIMPLE) for Newly Diagnosed and Relapsed/Refractory NK/T Cell Malignancies"
  findings: []
- reference: clinicaltrials:NCT03719105
  title: Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study
  findings: []
- reference: clinicaltrials:NCT05863234
  title: Multicenter, Open-label, Dose-escalation Phase I/II Study to Evaluate the Tolerability, Safety, Efficacy and Pharmacokinetics of Repeated Continuous Intravenous PPMX-T003 in Patients With Aggressive NK Cell Leukaemia (ANKL) (Physician-initiated Clinical Trial)
  findings: []
notes: >-
  Falcon deep research was completed on 2026-05-11 and the entry was re-reviewed
  on 2026-07-17. Curation emphasizes exact cache-backed evidence and separates
  association from causal directness. The Tang 2017 “subacute” course is retained
  as a cohort-proposed progression pattern rather than an established subtype.
  The 2026 ANKL22 cohort contextualizes historical survival estimates and current
  retrospective support for SMILE followed by allogeneic HSCT.

📚

References & Deep Research

References

11

DOI:10.3390/cancers12102900

Aggressive NK Cell Leukemia: Current State of the Art

No top-level findings curated for this source.

DOI:10.3389/frhem.2024.1413794

Case report: Aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent

No top-level findings curated for this source.

DOI:10.1097/pas.0000000000001518

Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia

No top-level findings curated for this source.

DOI:10.1038/s41467-018-03987-2

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target

No top-level findings curated for this source.

PMID:29263371

Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes.

No top-level findings curated for this source.

DOI:10.1155/crh/7796972

Aggressive Natural Killer Cell Leukemia: A Rare and Rapidly Progressive Hematologic Malignancy—Case Report and Literature Review

No top-level findings curated for this source.

PMID:41501503

Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.

No top-level findings curated for this source.

PMID:37870698

Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders.

No top-level findings curated for this source.

clinicaltrials:NCT03623087

Combination Chemotherapy Using Cisplatin, Gemcitabine, Ifosfamide, Etoposide, L-asparaginase and Dexamethasone (SIMPLE) for Newly Diagnosed and Relapsed/Refractory NK/T Cell Malignancies

No top-level findings curated for this source.

clinicaltrials:NCT03719105

Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study

No top-level findings curated for this source.

clinicaltrials:NCT05863234

Multicenter, Open-label, Dose-escalation Phase I/II Study to Evaluate the Tolerability, Safety, Efficacy and Pharmacokinetics of Repeated Continuous Intravenous PPMX-T003 in Patients With Aggressive NK Cell Leukaemia (ANKL) (Physician-initiated Clinical Trial)

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Aggressive NK-cell Leukemia (ANKL) — Comprehensive Disease Characteristics Report

Edison Scientific Literature 29 citations 2026-05-11T14:04:19.824446

Aggressive NK-cell Leukemia (ANKL) — Comprehensive Disease Characteristics Report

Target Disease

Disease name: Aggressive NK-cell leukemia (ANKL)
Category: Mature NK-cell neoplasm; EBV-associated T/NK-cell neoplasia spectrum
MONDO ID: Not available from the retrieved sources in this run (needs dedicated ontology lookup outside the current evidence set).

Evidence summary table

Domain	Key points	Quantitative data	Key source (with year, journal)	URL
Definition / classification	ANKL is a rare, fulminant, systemic mature NK-cell neoplasm with acute presentation and grave prognosis; recent reviews note it remains recognized in modern WHO/ICC-era classification of mature T/NK-cell neoplasms. It is distinct from extranodal NK/T-cell lymphoma, though overlap exists in disseminated disease. (hussein2020aggressivenkcell pages 1-3, spaner2024casereportaggressive pages 1-2, ferry2024maturebt pages 8-10)	Median age around 40 years in review cohorts; fewer than 500 cases reported overall in literature summaries. (hussein2020aggressivenkcell pages 1-3, spaner2024casereportaggressive pages 1-2)	El Hussein et al., 2020, Cancers; Spaner et al., 2024, Frontiers in Hematology; Ferry et al., 2024, J Hematol Oncol	https://doi.org/10.3390/cancers12102900
EBV association	EBV is strongly associated with ANKL and is detectable in most cases by EBER; however, EBV-negative ANKL exists and can show similar clinicopathologic features. ANKL often sits within the spectrum of EBV-associated T/NK-cell lymphoproliferative diseases. (hussein2020genomicandimmunophenotypic pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2, tang2017aggressivenkcellleukemia pages 1-2, hussein2020aggressivenkcell pages 3-5)	~90% EBV-driven in a 2024 case review; ~10% EBV-negative in older review; EBER positive in 9/12 cases in one clinicopathologic series. (spaner2024casereportaggressive pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2, hussein2020genomicandimmunophenotypic pages 1-2)	Hussein et al., 2020, Am J Surg Pathol; Ishida, 2018, Front Pediatr; Spaner et al., 2024, Front Hematol	https://doi.org/10.1097/pas.0000000000001518
Typical presentation / phenotypes	Common features include fever, constitutional symptoms, hepatosplenomegaly, liver dysfunction, leukemic blood picture, cytopenias, HLH/hemophagocytosis, DIC/coagulopathy, and multiorgan failure; nasal/skin lesions are less common than marrow, blood, liver, and spleen involvement. (hussein2020aggressivenkcell pages 1-3, ni2024clinicopathologicalfeaturesand pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2, spaner2024casereportaggressive pages 1-2)	HLH reported in ~60–90% in pediatric case literature summary; in one 12-case series, HLH in 2/12; common involved organs include marrow, peripheral blood, liver, spleen, lymph nodes. (ni2024clinicopathologicalfeaturesand pages 1-2, hussein2020genomicandimmunophenotypic pages 1-2)	Ni et al., 2024, Turkish Journal of Pediatrics; El Hussein et al., 2020, Cancers; Ishida, 2018, Front Pediatr	https://doi.org/10.24953/turkjpediatr.2024.5072
Diagnostic immunophenotype	Characteristic phenotype is NK-lineage with surface CD3 negative and cytoplasmic CD3ε positive; typically CD56+, CD2+, CD94+, cytotoxic marker positive (granzyme B, TIA1, perforin), usually negative for CD4, CD5, CD57, TCR αβ/γδ, and often lacking KIR expression. Bone marrow involvement may be interstitial or sinusoidal/intrasinusoidal. (hussein2020genomicandimmunophenotypic pages 1-2, hussein2020aggressivenkcell pages 3-5, hussein2020genomicandimmunophenotypic pages 2-3)	In one 12-case series: CD56+ 12/12, CD94+ 9/9, CD2+ 10/12, EBER+ 9/12; negative in all tested for surface CD3 12/12, CD5 11/11, CD57 9/9, TCRαβ 11/11, TCRγδ 11/11. Marrow ANKL fraction ranged 1.5% to 96.4%, median 22.5%. (hussein2020genomicandimmunophenotypic pages 1-2, hussein2020genomicandimmunophenotypic pages 2-3)	El Hussein et al., 2020, Am J Surg Pathol	https://doi.org/10.1097/pas.0000000000001518
Genetics / pathways	Recurrent alterations cluster in JAK/STAT activation, epigenetic dysregulation, TP53/DNA-repair impairment, and RAS/MAPK signaling; IL10-STAT3-MYC biosynthetic axis and HACE1 hypermethylation have been implicated. (hussein2020aggressivenkcell pages 1-3, ishida2018aggressivenkcellleukemia pages 1-2, tang2017aggressivenkcellleukemia pages 1-2, dufva2018aggressivenaturalkillercell pages 3-4)	Dufva et al.: STAT3 21%, RAS-MAPK genes 21%, DDX3X 29%, epigenetic modifiers 50%; copy-gain/mutation events affecting JAK2/STAT3/STAT5B also reported. Other summaries report TP53 34%, TET2 28%, CREBBP 21%, MLL2/KMT2D 21%, JAK-STAT pathway alterations ~48%, STAT3 mutations ~17%. (dufva2018aggressivenaturalkillercell pages 3-4, ishida2018aggressivenkcellleukemia pages 1-2, sumbly2022aggressivenaturalkiller pages 2-3)	Dufva et al., 2018, Nat Commun; Ishida, 2018, Front Pediatr; Sumbly et al., 2022, Cureus	https://doi.org/10.1038/s41467-018-03987-2
Epidemiology / demographics	ANKL is very rare, with geographic enrichment in Asian and Central/South American populations; most patients are young to middle-aged adults, though pediatric and older adult cases occur. Male predominance is reported in some cohorts. (hussein2020aggressivenkcell pages 1-3, ishida2018aggressivenkcellleukemia pages 1-2, tang2017aggressivenkcellleukemia pages 1-2)	Chinese multicenter cohort: age peak 21–30 years was 29.2% (33/113); male:female ratio nearly 2:1 in that decade. Western clinicopathologic series: median age 47.5 years, 9 men/3 women. (tang2017aggressivenkcellleukemia pages 1-2, hussein2020genomicandimmunophenotypic pages 1-2)	Tang et al., 2017, Blood Cancer Journal; El Hussein et al., 2020, Am J Surg Pathol	https://doi.org/10.1038/s41408-017-0021-z
Prognosis	Prognosis is extremely poor without effective induction and consolidation; many reviews cite median survival under 2–3 months. A subacute subtype with prolonged prodrome may have better outcomes than classic fulminant ANKL. (hussein2020aggressivenkcell pages 1-3, ni2024clinicopathologicalfeaturesand pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2, tang2017aggressivenkcellleukemia pages 1-2, spaner2024casereportaggressive pages 1-2)	Median OS 55 days and 1-year survival 4.42% (5/113) in a large cohort; median survival 2 months in a 12-case Western series; review summaries report median survival <2 to <3 months. (tang2017aggressivenkcellleukemia pages 1-2, hussein2020genomicandimmunophenotypic pages 1-2, ni2024clinicopathologicalfeaturesand pages 1-2)	Tang et al., 2017, Blood Cancer Journal; El Hussein et al., 2020, Am J Surg Pathol; Ni et al., 2024, Turkish Journal of Pediatrics	https://doi.org/10.1038/s41408-017-0021-z
Treatment: asparaginase-based therapy	Anthracycline-only approaches are generally ineffective; L-asparaginase/pegaspargase-containing regimens are the main active induction strategy. Regimens used include SMILE, AspaMetDex, L-GemOx, and related protocols. (ni2024clinicopathologicalfeaturesand pages 1-2, tang2017aggressivenkcellleukemia pages 1-2)	In Tang et al., among 13 newly diagnosed patients treated with AspaMetDex alone: CR 30.77% (4/13), ORR 76.92% (10/13), median OS 115 days; grade 3–4 hematologic AEs in 53.84% (7/13). Ni et al. summarize chemotherapy CR rate as <36%. (tang2017aggressivenkcellleukemia pages 1-2, ni2024clinicopathologicalfeaturesand pages 1-2)	Tang et al., 2017, Blood Cancer Journal; Ni et al., 2024, Turkish Journal of Pediatrics	https://doi.org/10.1038/s41408-017-0021-z
Treatment: allo-HSCT / outcomes	Allogeneic HSCT is the only modality consistently associated with durable survival in fit responders and is typically pursued after remission induction with asparaginase-based chemotherapy. (tang2017aggressivenkcellleukemia pages 1-2, ni2024clinicopathologicalfeaturesand pages 1-2)	In Tang et al., 7 patients underwent allo-HSCT after CR; median time to transplant 73 days, median OS 300 days, 2-year OS 42.86% (3/7). Ni et al. summarize ~55.5% relapse/progression within 1 year after allo-HSCT. (tang2017aggressivenkcellleukemia pages 1-2, ni2024clinicopathologicalfeaturesand pages 1-2)	Tang et al., 2017, Blood Cancer Journal; Ni et al., 2024, Turkish Journal of Pediatrics	https://doi.org/10.1038/s41408-017-0021-z
Emerging / targeted therapy rationale	Genomic profiling and drug sensitivity studies support investigation of JAK inhibitors, BCL2 inhibition, and immune checkpoint blockade in selected cases, especially where JAK/STAT activation or PD-L1 expression is present. These remain emerging rather than standard ANKL therapies. (hussein2020genomicandimmunophenotypic pages 1-2, hussein2020aggressivenkcell pages 1-3, dufva2018aggressivenaturalkillercell pages 3-4)	pSTAT3 positivity in 3/8 and PD-L1 positivity in 2/8 in one immunophenotypic series; Dufva et al. found NK malignancies highly sensitive to JAK and BCL2 inhibition in drug profiling. (hussein2020genomicandimmunophenotypic pages 1-2, dufva2018aggressivenaturalkillercell pages 3-4)	El Hussein et al., 2020, Am J Surg Pathol; Dufva et al., 2018, Nat Commun	https://doi.org/10.1038/s41467-018-03987-2

Table: This table condenses core disease facts for aggressive NK-cell leukemia, including classification, EBV association, presentation, diagnostic phenotype, genomics, prognosis, and treatment outcomes. It is useful as a quick evidence-backed reference for building a disease knowledge base entry.

1. Disease information

1.1 Concise overview (current understanding)

Aggressive NK-cell leukemia (ANKL) is a rare, fulminant systemic malignancy of mature natural killer (NK) cells with acute presentation, frequent cytokine-driven inflammatory complications (e.g., HLH), and very poor survival without rapid disease control and consolidation. Reviews emphasize that its acute clinical syndrome overlaps with other entities (notably EBV-associated lymphoproliferative disorders and NK/T-cell lymphomas), complicating early recognition and resulting in delayed diagnosis and treatment. (hussein2020aggressivenkcell pages 1-3, spaner2024casereportaggressive pages 1-2)

Direct abstract quote (example): “Aggressive natural killer cell leukemia (ANKL) is a rare, aggressive hematologic malignancy which often presents as fulminant Epstein-Barr virus (EBV)- driven hemophagocytic lymphohistiocytosis (HLH).” (spaner2024casereportaggressive pages 1-2)

1.2 Key identifiers and ontologies

WHO/ICC framing: The current hematopathology ecosystem includes WHO-HAEM5 (2022) and ICC (2022); comparative reviews summarize entity families and naming across systems. A classification comparison review provides the context that WHO-HAEM5 and ICC are the operative modern frameworks for mature B/T/NK neoplasms, and that EBV-positive T/NK entities are explicitly treated as a family. (ferry2024maturebt pages 8-10)
ICD/MeSH/OMIM/Orphanet: Not extractable from the current retrieved evidence set; these require targeted queries to OMIM/Orphanet/MeSH.

1.3 Synonyms / alternative names

“Aggressive NK-cell leukemia” (most common)
“Aggressive NK-cell leukaemia” (UK spelling)
Some literature uses “aggressive NK-cell leukemia/lymphoma” in broader discussions of NK-cell malignancies. (ishida2018aggressivenkcellleukemia pages 1-2, NCT03623087 chunk 1)

1.4 Evidence source types in this report

Aggregated disease-level resources: pathology/oncology reviews and classification comparison reviews (hussein2020aggressivenkcell pages 1-3, ferry2024maturebt pages 8-10)
Human clinical primary studies: multicenter cohort (n=113) (tang2017aggressivenkcellleukemia pages 1-2), clinicopathologic series with IHC/NGS (n=12) (hussein2020genomicandimmunophenotypic pages 1-2, hussein2020genomicandimmunophenotypic pages 2-3)
Human genomic/translational primary studies: WES + drug profiling (n=14) (dufva2018aggressivenaturalkillercell pages 3-4, dufva2018aggressivenaturalkillercell media 01c6d37e, dufva2018aggressivenaturalkillercell media 2b03bded)
Case-based recent literature (2024): adolescent/pediatric cases emphasizing HLH and diagnostic delays (ni2024clinicopathologicalfeaturesand pages 1-2, spaner2024casereportaggressive pages 1-2)

2. Etiology

2.1 Disease causal factors

Epstein–Barr virus (EBV) association

ANKL is commonly EBV-associated, with EBER positivity in the majority of cases in multiple series, and many reviews describing EBV as a driver in ~90% of cases (though EBV-negative ANKL exists). (hussein2020genomicandimmunophenotypic pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2, spaner2024casereportaggressive pages 1-2)

Clinicopathologic series: EBER was positive in 9/12 ANKL cases. (hussein2020genomicandimmunophenotypic pages 1-2)
Review synthesis: ~10% EBV-negative in one review; EBV-negative cases may present in middle-aged adults and can resemble EBV-positive ANKL clinically/pathologically. (ishida2018aggressivenkcellleukemia pages 1-2, sumbly2022aggressivenaturalkiller pages 2-3)

2.2 Risk factors

Geography/ancestry: Cohort and review literature repeatedly notes predilection for Asian populations and Central/South America, consistent with EBV-associated NK/T neoplasia geography. (hussein2020aggressivenkcell pages 1-3, tang2017aggressivenkcellleukemia pages 1-2)
Pre-existing EBV-associated immune dysregulation: Several 2024 reports frame ANKL as arising in/with EBV-driven HLH contexts and discuss overlap with chronic active EBV disease in differential diagnosis. (spaner2024casereportaggressive pages 1-2)

Note: Specific germline genetic susceptibility loci or robust environmental risk factors were not retrievable from the current evidence set.

2.3 Protective factors

No protective factors (genetic or environmental) were identified in the retrieved evidence.

2.4 Gene–environment interactions

Not established in retrieved evidence; EBV infection is a biological exposure interacting with host immune status and tumor genetics, but formal GxE data were not found here.

3. Phenotypes (clinical features)

3.1 Core phenotype spectrum

ANKL commonly presents with an acute systemic inflammatory and hematologic syndrome including: - Fever / constitutional symptoms (symptom) - Hepatosplenomegaly (clinical sign) - Cytopenias and leukemic blood picture (laboratory abnormality) - Liver dysfunction / acute liver injury (laboratory and organ phenotype) - Coagulopathy / DIC (laboratory abnormality, complication) - Hemophagocytic lymphohistiocytosis (HLH) (immune dysregulation syndrome) - Multiorgan failure in severe/refractory disease These are repeatedly highlighted across reviews, cohorts, and 2024 case literature. (hussein2020aggressivenkcell pages 1-3, ni2024clinicopathologicalfeaturesand pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2, spaner2024casereportaggressive pages 1-2, hussein2020genomicandimmunophenotypic pages 2-3)

Direct abstract quotes (examples): - “Patients commonly present acutely with fever, constitutional symptoms, hepatosplenomegaly, and often disseminated intravascular coagulation or hemophagocytic syndrome.” (sumbly2022aggressivenaturalkiller pages 2-3) - “HLH can serve as the initial manifestation of ANKL.” (ni2024clinicopathologicalfeaturesand pages 1-2)

3.2 Age of onset, severity, progression

Typical onset: young to middle-aged adults; however, pediatric/adolescent cases occur. (ni2024clinicopathologicalfeaturesand pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2, tang2017aggressivenkcellleukemia pages 1-2)
Course: fulminant/rapidly progressive in most patients; a “subacute” clinical subtype with prolonged IM-like prodrome (>90 days; median 115 days) was identified in a large cohort. (tang2017aggressivenkcellleukemia pages 2-4)

3.3 Frequency (where available)

HLH frequency: A 2024 pediatric-focused review notes HLH is common; in a separate case-literature preprint, HLH co-occurrence is described as frequent; quantitative, cohort-level HLH prevalence was not consistently extractable from all sources here. (ni2024clinicopathologicalfeaturesand pages 1-2)

3.4 Quality of life impact

Formal QoL instruments (EQ-5D/SF-36/PROMIS) were not identified in retrieved evidence. Clinical impact is inferred from fulminant symptoms, ICU-level complications (DIC, multiorgan failure), and extremely short survival. (hussein2020aggressivenkcell pages 1-3, tang2017aggressivenkcellleukemia pages 1-2)

3.5 Suggested HPO terms (non-exhaustive)

Fever HP:0001945
Hepatosplenomegaly HP:0001433 (or hepatomegaly HP:0002240; splenomegaly HP:0001744)
Pancytopenia HP:0001876
Thrombocytopenia HP:0001873
Elevated lactate dehydrogenase HP:0003236
Disseminated intravascular coagulation HP:0001907
Hemophagocytic lymphohistiocytosis HP:0031425
Acute liver failure HP:0006557 / abnormal liver function tests HP:0002910

4. Genetic / molecular information

4.1 Causal genes

ANKL is not a monogenic germline disorder in the retrieved evidence. It is characterized by somatic alterations and pathway dysregulation.

4.2 Recurrently altered genes and pathways (with frequencies)

Multiple sources converge on three major molecular themes: JAK/STAT activation, epigenetic dysregulation, and TP53/DNA repair impairment, with additional contribution from RAS/MAPK signaling. (hussein2020aggressivenkcell pages 1-3, dufva2018aggressivenaturalkillercell pages 3-4)

JAK/STAT pathway

WES study (n=14): STAT3 mutations ~21%; copy-number and other alterations implicating JAK/STAT signaling were emphasized. (dufva2018aggressivenaturalkillercell pages 3-4)
Review synthesis: JAK-STAT pathway alterations reported ~48% overall in some summaries. (sumbly2022aggressivenaturalkiller pages 2-3)

Visual evidence from Dufva et al. shows JAK-STAT component alterations and copy-number gains and summarizes frequencies across cohorts (including JAK2/STAT3/STAT5 alterations). (dufva2018aggressivenaturalkillercell media 01c6d37e, dufva2018aggressivenaturalkillercell media 2b03bded)

Epigenetic modifiers

WES study: epigenetic modifier mutations reported in ~50%. (dufva2018aggressivenaturalkillercell pages 3-4)
Review synthesis lists TET2 (28%), CREBBP (21%), MLL2/KMT2D (21%) among recurrent events in a summarized cohort. (sumbly2022aggressivenaturalkiller pages 2-3, ishida2018aggressivenkcellleukemia pages 1-2)

TP53 pathway

Review synthesis reports TP53 mutations ~34%. (sumbly2022aggressivenaturalkiller pages 2-3, ishida2018aggressivenkcellleukemia pages 1-2)
A large cohort found TP53 mutations enriched in classic (fulminant) ANKL (37.93%, 11/29 in sequenced classic ANKL), absent in subacute ANKL subtype in that cohort’s sequencing subset. (tang2017aggressivenkcellleukemia pages 2-4)
Clinicopathologic series: aberrant p53 expression was common (7/8 by IHC), with TP53 mutations detected in 3/6 in the NGS subset. (hussein2020genomicandimmunophenotypic pages 1-2)

DDX3X and RAS/MAPK

WES study: DDX3X ~29%, RAS-MAPK pathway genes ~21%. (dufva2018aggressivenaturalkillercell pages 3-4)

4.3 Epigenetics

ANKL epigenetic dysregulation is supported by recurrent mutations in epigenetic modifiers and literature noting methylation events (e.g., HACE1 hypermethylation mentioned in the large cohort background). (tang2017aggressivenkcellleukemia pages 1-2, hussein2020aggressivenkcell pages 1-3)

4.4 Chromosomal abnormalities

Clonal cytogenetic abnormalities are reported in clinical series (5/12 in one series). (hussein2020genomicandimmunophenotypic pages 1-2)

4.5 Mechanistic chain (pathophysiology synthesis)

A plausible causal chain supported by current evidence is: 1) EBV infection of NK lineage cells (EBER+) and/or host immune dysregulation contributes to transformation and/or inflammatory phenotype. (hussein2020genomicandimmunophenotypic pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2) 2) Somatic alterations (JAK/STAT activation; epigenetic modifier and TP53 pathway lesions; RAS/MAPK) promote malignant proliferation, survival, and immune evasion. (dufva2018aggressivenaturalkillercell pages 3-4, tang2017aggressivenkcellleukemia pages 2-4) 3) NK-cell cytokine programs and pathway-driven transcriptional changes (including IL10–STAT3–MYC axis described in reviews) contribute to “cytokine storm” physiology and HLH-like systemic inflammation. (hussein2020genomicandimmunophenotypic pages 1-2, hussein2020aggressivenkcell pages 3-5) 4) Downstream manifestations include cytopenias, HLH, DIC, liver dysfunction, and multiorgan failure, driving high early mortality. (hussein2020aggressivenkcell pages 1-3, tang2017aggressivenkcellleukemia pages 1-2)

4.6 Suggested ontology terms

GO biological process (examples): JAK-STAT cascade (GO:0007259), cytokine-mediated signaling pathway (GO:0019221), regulation of apoptotic process (GO:0042981), leukocyte proliferation (GO:0070661)
Cell Ontology (CL) (examples): natural killer cell CL:0000623; malignant NK cell (no single CL term; represent as NK cell + neoplastic context)

5. Environmental information

Infectious agents

EBV (Epstein–Barr virus) is the central infectious association; tumor EBER positivity is common. (hussein2020genomicandimmunophenotypic pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2)

Other environmental and lifestyle associations were not identified in retrieved evidence.

6. Mechanism / pathophysiology

6.1 Molecular pathways (high-confidence)

JAK/STAT signaling activation as a recurring pathway with STAT3/STAT5 and copy-number events. (dufva2018aggressivenaturalkillercell pages 3-4, dufva2018aggressivenaturalkillercell media 01c6d37e, dufva2018aggressivenaturalkillercell media 2b03bded)
Epigenetic dysregulation (TET2/CREBBP/KMT2D and other epigenetic modifiers). (sumbly2022aggressivenaturalkiller pages 2-3, dufva2018aggressivenaturalkillercell pages 3-4)
TP53 impairment (mutation and/or aberrant protein expression). (hussein2020genomicandimmunophenotypic pages 1-2, tang2017aggressivenkcellleukemia pages 2-4)
RAS/MAPK activation subset. (dufva2018aggressivenaturalkillercell pages 3-4)

6.2 Immune involvement

ANKL frequently presents with HLH and systemic inflammation; NK lineage biology (cytokine secretion programs) is implicated as a contributor to cytokine storm physiology in reviews. (hussein2020aggressivenkcell pages 3-5, spaner2024casereportaggressive pages 1-2)

6.3 Molecular profiling / multi-omics

Genomics: WES and targeted sequencing characterize recurrent pathways; Dufva et al. provides integrated genomics + drug sensitivity profiling highlighting pathway vulnerabilities. (dufva2018aggressivenaturalkillercell pages 3-4)

Not found in retrieved evidence: single-cell or spatial transcriptomics dedicated to ANKL.

7. Anatomical structures affected

7.1 Organ level

Commonly involved sites include bone marrow and peripheral blood, with frequent involvement of liver and spleen; lymph nodes may be involved; less commonly skin/soft tissue/lung are described in recent pediatric case review. (ni2024clinicopathologicalfeaturesand pages 1-2, ishida2018aggressivenkcellleukemia pages 1-2)

7.2 Tissue/cell level

Targeted population: neoplastic NK cells infiltrating marrow and other organs. (hussein2020genomicandimmunophenotypic pages 1-2)

7.3 Suggested UBERON terms (examples)

Bone marrow: UBERON:0002371
Spleen: UBERON:0002106
Liver: UBERON:0002107
Peripheral blood: UBERON:0000178

8. Temporal development

8.1 Onset pattern

Often acute with rapidly progressive systemic illness prompting “acute leukemia” evaluation. (hussein2020genomicandimmunophenotypic pages 2-3)

8.2 Progression

A large cohort distinguished: - Classic ANKL: fulminant presentation and very short OS. - Subacute ANKL subtype: prolonged prodromal IM-like phase >90 days (median 115 days) before fulminant onset, with survival advantage and differing TP53 mutation enrichment. (tang2017aggressivenkcellleukemia pages 2-4)

9. Inheritance and population

9.1 Epidemiology

Robust population incidence/prevalence rates were not found in the retrieved evidence (likely due to rarity and registry limitations). The largest cohort notes extreme rarity (hundreds of cases in the literature) and geographic predilection. (tang2017aggressivenkcellleukemia pages 1-2, hussein2020aggressivenkcell pages 1-3)

9.2 Demographics (quantitative)

Age peak: 21–30 years accounted for 29.2% (33/113) in a multicenter Chinese cohort. (tang2017aggressivenkcellleukemia pages 1-2)
Sex: male:female ratio nearly 2:1 in that decade in the same cohort. (tang2017aggressivenkcellleukemia pages 1-2)
Western series: median age 47.5 years; 9 men and 3 women. (hussein2020genomicandimmunophenotypic pages 2-3)

9.3 Inheritance

No germline inheritance pattern is established in retrieved evidence; ANKL is characterized by somatic oncogenic alterations.

10. Diagnostics

10.1 Diagnostic approach (real-world)

ANKL diagnosis is challenging due to variable morphology and lack of a single defining marker; it requires integration of: - Peripheral blood and bone marrow morphology - Flow cytometry (NK immunophenotype) - EBV testing (EBER ISH) - IHC and NGS when feasible In a clinicopathologic series, the acute presentation triggered marrow sampling with suspicion of acute leukemia. (hussein2020genomicandimmunophenotypic pages 2-3)

10.2 Immunophenotype (high-yield diagnostic signature)

Across series and reviews, a core pattern includes: - Positive: CD56, CD94, CD2; cytotoxic markers (granzyme B, TIA-1, perforin); often EBER+ (EBV-associated subset) - Negative: surface CD3, CD4, CD5, CD57; TCRαβ/γδ - Bone marrow patterns: interstitial or intrasinusoidal/sinusoidal infiltration patterns. (hussein2020genomicandimmunophenotypic pages 1-2, hussein2020aggressivenkcell pages 3-5, hussein2020genomicandimmunophenotypic pages 2-3)

Quantitative immunophenotype from a 12-case series: CD56+ (12/12), CD94+ (9/9), CD2+ (10/12), EBER+ (9/12); surface CD3− (12/12), CD5− (11/11), CD57− (9/9), TCRαβ− (11/11), TCRγδ− (11/11). (hussein2020genomicandimmunophenotypic pages 1-2)

10.3 Differential diagnosis (examples)

EBV-driven HLH without neoplasia vs ANKL presenting as EBV-HLH (emphasized in 2024 adolescent case literature). (spaner2024casereportaggressive pages 1-2)
Extranodal NK/T-cell lymphoma with leukemic/disseminated phase (clinical overlap discussed in reviews). (hussein2020aggressivenkcell pages 1-3)

10.4 Suggested tests / biomarkers

EBER ISH in marrow/tissue
Flow cytometry with NK markers (CD56, CD94, CD16, CD2; absence of surface CD3/TCR)
Plasma EBV DNA (used in related NK/T malignancies; specific ANKL thresholds not established in retrieved evidence)

11. Outcome / prognosis

11.1 Key statistics

Median overall survival: 55 days in a multicenter cohort (n=113). (tang2017aggressivenkcellleukemia pages 1-2)
1-year survival: 4.42% (5/113) in that cohort. (tang2017aggressivenkcellleukemia pages 1-2)
Median survival ~2 months: reported in a Western clinicopathologic series and cited broadly in reviews. (hussein2020genomicandimmunophenotypic pages 1-2, hussein2020aggressivenkcell pages 1-3)

11.2 Prognostic factors (reported)

Univariate/multivariate analyses in the large cohort identified clinical subtype, LDH, and treatment modality as prognostic; administration of L-asparaginase-based chemotherapy and allo-HSCT were associated with improved survival. (tang2017aggressivenkcellleukemia pages 2-4)

12. Treatment

12.1 Standard practice (current real-world implementation)

Evidence across cohorts/reviews supports: 1) L-asparaginase (or pegylated asparaginase)–containing induction chemotherapy (e.g., SMILE, AspaMetDex, related regimens) 2) Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in eligible responders Despite these strategies, outcomes remain poor for many patients due to rapid progression and treatment-related toxicity in critically ill presentations. (ni2024clinicopathologicalfeaturesand pages 1-2, tang2017aggressivenkcellleukemia pages 1-2, tang2017aggressivenkcellleukemia pages 2-4)

12.2 Chemotherapy outcomes (quantitative)

In Tang et al. (n=113 cohort), among 13 newly diagnosed patients treated with AspaMetDex chemotherapy alone: - CR: 30.77% (4/13) - ORR: 76.92% (10/13) - Median OS: 115 days (range 37–450) - Grade 3–4 hematologic AEs: 53.84% (7/13) These data highlight that responses are achievable, but durability is limited without consolidation. (tang2017aggressivenkcellleukemia pages 2-4)

A 2024 pediatric case review notes chemotherapy CR rates overall as <36% and summarizes that allo-HSCT still has high relapse/progression within 1 year (~55.5%). (ni2024clinicopathologicalfeaturesand pages 1-2)

12.3 Allo-HSCT outcomes (quantitative)

In Tang et al., 7 patients underwent allo-HSCT after CR: - Median OS: 300 days (range 174–1480) - 2-year OS: 42.86% (3/7) This supports allo-HSCT as a key consolidation strategy when remission is achieved and a donor is available. (tang2017aggressivenkcellleukemia pages 2-4)

12.4 Emerging/targeted therapies (expert analysis)

Genomic and drug profiling evidence indicates potential vulnerabilities: - JAK inhibition (for JAK/STAT-activated disease) - BCL2 inhibition (drug sensitivity profiling highlighted NK cells’ sensitivity) - Immune checkpoint blockade in selected contexts (PD-L1 expression reported in a subset) These approaches are not yet established as standard-of-care in the retrieved evidence but are rationally motivated by the genomic landscape. (hussein2020genomicandimmunophenotypic pages 1-2, dufva2018aggressivenaturalkillercell pages 3-4)

12.5 Clinical trials (NCT identifiers)

NCT03719105 (start 2019-03-01; Early Phase 1; Recruiting): Modified SMILE (mSMILE) including calaspargase pegol; pembrolizumab added for <CR after 2 cycles; followed by allo-HSCT when possible; explicitly includes ANKL in cohort 1. (NCT03719105 chunk 1)
URL: https://clinicaltrials.gov/study/NCT03719105
NCT03623087 (start 2017-07-01; Phase 3; status uncertain in record): “SIMPLE” chemotherapy regimen (cisplatin, gemcitabine, ifosfamide, etoposide, L-asparaginase, dexamethasone) designed as non-inferiority vs SMILE and includes aggressive NK leukaemia among target conditions. (NCT03623087 chunk 1)
URL: https://clinicaltrials.gov/study/NCT03623087
NCT05863234 (2023; Phase I/II; Recruiting; n=7): PPMX-T003 continuous IV administration safety/PK study in ANKL; excludes patients eligible for chemotherapy. (NCT05863234 chunk 1)
URL: https://clinicaltrials.gov/study/NCT05863234

12.6 Suggested MAXO terms (examples)

Chemotherapy MAXO:0000647
L-asparaginase therapy (map as chemotherapy + specific drug exposure; MAXO may not have a dedicated asparaginase term)
Allogeneic hematopoietic stem cell transplantation MAXO:0000747 (or closest HSCT term depending on MAXO release)
Immune checkpoint inhibitor therapy (immunotherapy; PD-1 inhibitor)

13. Prevention

No primary prevention strategies are established for ANKL in retrieved evidence. Prevention is largely not applicable beyond general EBV disease management and immunosuppression/immune dysregulation surveillance in high-risk contexts (not quantified here).

14. Other species / natural disease

No naturally occurring veterinary analogs were identified in retrieved evidence.

15. Model organisms

No dedicated animal models were identified in the retrieved evidence. The strongest mechanistic evidence here is from human tumor genomics and ex vivo drug sensitivity profiling. (dufva2018aggressivenaturalkillercell pages 3-4)

Recent developments & 2023–2024 highlights (prioritized)

1) 2024 case-based literature emphasizes that ANKL may present as refractory EBV-HLH and that lack of a “distinct immunologic and morphologic signature” delays diagnosis; early, repeated marrow/peripheral blood flow cytometry is highlighted as critical. (spaner2024casereportaggressive pages 1-2) 2) 2024 pediatric case series supports the operational treatment strategy of intensive pegaspargase/anthracycline-containing chemotherapy with consideration of HSCT, while underscoring high early mortality (e.g., tumor lysis) and the need for rapid supportive care. (ni2024clinicopathologicalfeaturesand pages 1-2) 3) WHO/ICC-era classification synthesis (2024) provides clinicians/pathologists a consolidated view of how modern frameworks align, improving standardization of terminology and diagnostic categorization for mature T/NK neoplasms. (ferry2024maturebt pages 8-10)

Key statistics (for knowledge base)

Median OS: 55 days (Tang et al., 2017; n=113). (tang2017aggressivenkcellleukemia pages 1-2)
1-year survival: 4.42% (5/113). (tang2017aggressivenkcellleukemia pages 1-2)
AspaMetDex induction (subset): CR 30.77%; ORR 76.92%; median OS 115 days; grade 3–4 hematologic AEs 53.84%. (tang2017aggressivenkcellleukemia pages 2-4)
Allo-HSCT (subset): 2-year OS 42.86% (3/7). (tang2017aggressivenkcellleukemia pages 2-4)

Visual evidence (genomic landscape)

Dufva et al. provide figure panels and a table summarizing JAK-STAT pathway alterations (mutations and copy-number gains) across ANKL cohorts and related NK/T malignancies; these visuals support the centrality of JAK/STAT dysregulation in ANKL and the rationale for pathway-directed therapy hypotheses. (dufva2018aggressivenaturalkillercell media 01c6d37e, dufva2018aggressivenaturalkillercell media 2b03bded)

Limitations of this evidence set

Several requested identifiers (MONDO, OMIM, Orphanet, MeSH, ICD-10/ICD-11) were not available from the retrieved texts in this run.
Many articles in this run do not provide PMIDs in the extracted text, so PMID-preferring citations cannot always be satisfied without additional PubMed-specific retrieval.
Incidence/prevalence rates and validated QoL measures were not found in the retrieved evidence.

References

(hussein2020aggressivenkcell pages 1-3): Siba El Hussein, L. Medeiros, and Joseph Khoury. Aggressive nk cell leukemia: current state of the art. Cancers, 12:2900, Oct 2020. URL: https://doi.org/10.3390/cancers12102900, doi:10.3390/cancers12102900. This article has 67 citations.
(spaner2024casereportaggressive pages 1-2): Caroline Spaner, Jessica Durkee-Shock, Andrew Weng, Ryan Stubbins, Alina S. Gerrie, Stefania Pittaluga, Jeffrey I. Cohen, and Luke Y. C. Chen. Case report: aggressive natural killer cell leukemia and refractory hemophagocytic lymphohistiocytosis in an adolescent. Frontiers in Hematology, Jul 2024. URL: https://doi.org/10.3389/frhem.2024.1413794, doi:10.3389/frhem.2024.1413794. This article has 0 citations.
(ferry2024maturebt pages 8-10): Judith A. Ferry, Brian Hill, and Eric D. Hsi. Mature b, t and nk-cell, plasma cell and histiocytic/dendritic cell neoplasms: classification according to the world health organization and international consensus classification. Journal of Hematology & Oncology, Jul 2024. URL: https://doi.org/10.1186/s13045-024-01570-5, doi:10.1186/s13045-024-01570-5. This article has 19 citations and is from a domain leading peer-reviewed journal.
(hussein2020genomicandimmunophenotypic pages 1-2): Siba El Hussein, Keyur P. Patel, Hong Fang, Beenu Thakral, Sanam Loghavi, Rashmi Kanagal-Shamanna, Sergej Konoplev, Elias J. Jabbour, L. Jeffrey Medeiros, and Joseph D. Khoury. Genomic and immunophenotypic landscape of aggressive nk-cell leukemia. The American Journal of Surgical Pathology, 44:1235-1243, Jun 2020. URL: https://doi.org/10.1097/pas.0000000000001518, doi:10.1097/pas.0000000000001518. This article has 46 citations.
(ishida2018aggressivenkcellleukemia pages 1-2): Fumihiro Ishida. Aggressive nk-cell leukemia. Frontiers in Pediatrics, Oct 2018. URL: https://doi.org/10.3389/fped.2018.00292, doi:10.3389/fped.2018.00292. This article has 66 citations.
(tang2017aggressivenkcellleukemia pages 1-2): Yuan Tang, D. Wang, H. Luo, M. Xiao, H-S Zhou, D. Liu, Shaoping Ling, N. Wang, X-L Hu, Y. Luo, X. Mao, Q. Ao, J. Huang, W. Zhang, L. Sheng, L. Zhu, Z. Shang, L. Gao, P-L Zhang, M. Zhou, K. Zhou, L. Qiu, Q.‐F. Liu, H.-Y. Zhang, J. Li, J. Jin, L. Fu, W-L Zhao, J-P Chen, X. Du, G. Huang, Q-f Wang, J. Zhou, and L. Huang. Aggressive nk-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. Blood Cancer Journal, Dec 2017. URL: https://doi.org/10.1038/s41408-017-0021-z, doi:10.1038/s41408-017-0021-z. This article has 72 citations and is from a domain leading peer-reviewed journal.
(hussein2020aggressivenkcell pages 3-5): Siba El Hussein, L. Medeiros, and Joseph Khoury. Aggressive nk cell leukemia: current state of the art. Cancers, 12:2900, Oct 2020. URL: https://doi.org/10.3390/cancers12102900, doi:10.3390/cancers12102900. This article has 67 citations.
(ni2024clinicopathologicalfeaturesand pages 1-2): Yongan Ni, Lei Li, Yuping Wang, and Lirong Sun. Clinicopathological features and treatment of aggressive natural killer cell leukemia: case series and literature review. The Turkish journal of pediatrics, 66 4:481-489, Oct 2024. URL: https://doi.org/10.24953/turkjpediatr.2024.5072, doi:10.24953/turkjpediatr.2024.5072. This article has 1 citations.
(hussein2020genomicandimmunophenotypic pages 2-3): Siba El Hussein, Keyur P. Patel, Hong Fang, Beenu Thakral, Sanam Loghavi, Rashmi Kanagal-Shamanna, Sergej Konoplev, Elias J. Jabbour, L. Jeffrey Medeiros, and Joseph D. Khoury. Genomic and immunophenotypic landscape of aggressive nk-cell leukemia. The American Journal of Surgical Pathology, 44:1235-1243, Jun 2020. URL: https://doi.org/10.1097/pas.0000000000001518, doi:10.1097/pas.0000000000001518. This article has 46 citations.
(dufva2018aggressivenaturalkillercell pages 3-4): Olli Dufva, Matti Kankainen, Tiina Kelkka, Nodoka Sekiguchi, Shady Adnan Awad, Samuli Eldfors, Bhagwan Yadav, Heikki Kuusanmäki, Disha Malani, Emma I Andersson, Paavo Pietarinen, Leena Saikko, Panu E. Kovanen, Teija Ojala, Dean A. Lee, Thomas P. Loughran, Hideyuki Nakazawa, Junji Suzumiya, Ritsuro Suzuki, Young Hyeh Ko, Won Seog Kim, Shih-Sung Chuang, Tero Aittokallio, Wing C. Chan, Koichi Ohshima, Fumihiro Ishida, and Satu Mustjoki. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight jak-stat signaling as therapeutic target. Nature Communications, Apr 2018. URL: https://doi.org/10.1038/s41467-018-03987-2, doi:10.1038/s41467-018-03987-2. This article has 163 citations and is from a highest quality peer-reviewed journal.
(sumbly2022aggressivenaturalkiller pages 2-3): Vikram Sumbly, Mallorie Vest, and Ian Landry. Aggressive natural killer cell leukemia: a brief overview of its genomic landscape, histological features, and current management. Cureus, Feb 2022. URL: https://doi.org/10.7759/cureus.22537, doi:10.7759/cureus.22537. This article has 17 citations.
(NCT03623087 chunk 1): Professor Yok-lam Kwong. SIMPLE Chemotherapy for NK Lymphoma/Leukaemia. The University of Hong Kong. 2017. ClinicalTrials.gov Identifier: NCT03623087
(dufva2018aggressivenaturalkillercell media 01c6d37e): Olli Dufva, Matti Kankainen, Tiina Kelkka, Nodoka Sekiguchi, Shady Adnan Awad, Samuli Eldfors, Bhagwan Yadav, Heikki Kuusanmäki, Disha Malani, Emma I Andersson, Paavo Pietarinen, Leena Saikko, Panu E. Kovanen, Teija Ojala, Dean A. Lee, Thomas P. Loughran, Hideyuki Nakazawa, Junji Suzumiya, Ritsuro Suzuki, Young Hyeh Ko, Won Seog Kim, Shih-Sung Chuang, Tero Aittokallio, Wing C. Chan, Koichi Ohshima, Fumihiro Ishida, and Satu Mustjoki. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight jak-stat signaling as therapeutic target. Nature Communications, Apr 2018. URL: https://doi.org/10.1038/s41467-018-03987-2, doi:10.1038/s41467-018-03987-2. This article has 163 citations and is from a highest quality peer-reviewed journal.
(dufva2018aggressivenaturalkillercell media 2b03bded): Olli Dufva, Matti Kankainen, Tiina Kelkka, Nodoka Sekiguchi, Shady Adnan Awad, Samuli Eldfors, Bhagwan Yadav, Heikki Kuusanmäki, Disha Malani, Emma I Andersson, Paavo Pietarinen, Leena Saikko, Panu E. Kovanen, Teija Ojala, Dean A. Lee, Thomas P. Loughran, Hideyuki Nakazawa, Junji Suzumiya, Ritsuro Suzuki, Young Hyeh Ko, Won Seog Kim, Shih-Sung Chuang, Tero Aittokallio, Wing C. Chan, Koichi Ohshima, Fumihiro Ishida, and Satu Mustjoki. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight jak-stat signaling as therapeutic target. Nature Communications, Apr 2018. URL: https://doi.org/10.1038/s41467-018-03987-2, doi:10.1038/s41467-018-03987-2. This article has 163 citations and is from a highest quality peer-reviewed journal.
(tang2017aggressivenkcellleukemia pages 2-4): Yuan Tang, D. Wang, H. Luo, M. Xiao, H-S Zhou, D. Liu, Shaoping Ling, N. Wang, X-L Hu, Y. Luo, X. Mao, Q. Ao, J. Huang, W. Zhang, L. Sheng, L. Zhu, Z. Shang, L. Gao, P-L Zhang, M. Zhou, K. Zhou, L. Qiu, Q.‐F. Liu, H.-Y. Zhang, J. Li, J. Jin, L. Fu, W-L Zhao, J-P Chen, X. Du, G. Huang, Q-f Wang, J. Zhou, and L. Huang. Aggressive nk-cell leukemia: clinical subtypes, molecular features, and treatment outcomes. Blood Cancer Journal, Dec 2017. URL: https://doi.org/10.1038/s41408-017-0021-z, doi:10.1038/s41408-017-0021-z. This article has 72 citations and is from a domain leading peer-reviewed journal.
(NCT03719105 chunk 1): Mitchell Cairo. Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma. New York Medical College. 2019. ClinicalTrials.gov Identifier: NCT03719105
(NCT05863234 chunk 1): Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia. Hiroshima University Hospital. 2023. ClinicalTrials.gov Identifier: NCT05863234

Ask OpenScientist

OpenScientist Report

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Progression

Infectious Agent

Differential Diagnoses

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

Aggressive NK-cell Leukemia (ANKL) — Comprehensive Disease Characteristics Report

Target Disease

Evidence summary table

1. Disease information

1.1 Concise overview (current understanding)

1.2 Key identifiers and ontologies

1.3 Synonyms / alternative names

1.4 Evidence source types in this report

2. Etiology

2.1 Disease causal factors

Epstein–Barr virus (EBV) association

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes (clinical features)

3.1 Core phenotype spectrum

3.2 Age of onset, severity, progression

3.3 Frequency (where available)

3.4 Quality of life impact

3.5 Suggested HPO terms (non-exhaustive)

4. Genetic / molecular information

4.1 Causal genes

4.2 Recurrently altered genes and pathways (with frequencies)

JAK/STAT pathway

Epigenetic modifiers

TP53 pathway

DDX3X and RAS/MAPK

4.3 Epigenetics

4.4 Chromosomal abnormalities

4.5 Mechanistic chain (pathophysiology synthesis)

4.6 Suggested ontology terms

5. Environmental information

Infectious agents

6. Mechanism / pathophysiology

6.1 Molecular pathways (high-confidence)

6.2 Immune involvement

6.3 Molecular profiling / multi-omics

7. Anatomical structures affected

7.1 Organ level

7.2 Tissue/cell level

7.3 Suggested UBERON terms (examples)

8. Temporal development

8.1 Onset pattern

8.2 Progression

9. Inheritance and population

9.1 Epidemiology

9.2 Demographics (quantitative)

9.3 Inheritance

10. Diagnostics

10.1 Diagnostic approach (real-world)

10.2 Immunophenotype (high-yield diagnostic signature)

10.3 Differential diagnosis (examples)

10.4 Suggested tests / biomarkers

11. Outcome / prognosis

11.1 Key statistics

11.2 Prognostic factors (reported)

12. Treatment

12.1 Standard practice (current real-world implementation)

12.2 Chemotherapy outcomes (quantitative)

12.3 Allo-HSCT outcomes (quantitative)

12.4 Emerging/targeted therapies (expert analysis)